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ABSTRACT: The aminergic family of G protein-coupled receptors (GPCRs) plays an important role in various diseases and
represents a major drug discovery target class. Structure determination of all major aminergic subfamilies has enabled structure-
based ligand design for these receptors. Site-directed mutagenesis data provides an invaluable complementary source of
information for elucidating the structural determinants of binding of different ligand chemotypes. The current study provides a
comparative analysis of 6692 mutation data points on 34 aminergic GPCR subtypes, covering the chemical space of 540 unique
ligands from mutagenesis experiments and information from experimentally determined structures of 52 distinct aminergic
receptor−ligand complexes. The integrated analysis enables detailed investigation of structural receptor−ligand interactions and
assessment of the transferability of combined binding mode and mutation data across ligand chemotypes and receptor subtypes.
An overview is provided of the possibilities and limitations of using mutation data to guide the design of novel aminergic
receptor ligands.
1. INTRODUCTION
G protein-coupled receptors (GPCRs) are an important family
of signal-transducing membrane proteins capable of binding
various types of ligands from the extracellular space and
activating various signaling pathways inside the cell, rendering
them one of the largest protein target families in
pharmaceutical research.1 In 2007, the first nonrhodopsin
GPCR was crystallized.2 Currently, stabilizing mutations,3,4
fusion constructs,5,6 and the use of antibodies7 allowed the
crystallization of more than 50 different GPCR subtypes with
various interacting partners and in different functional states,
covering more than 183 unique receptor−ligand complexes.8
This growing amount of structural information is invaluable for
understanding GPCR function and the structural determinants
of ligand binding and for structure-based design of novel
ligands. Receptors of the aminergic GPCR family are
particularly rewarding drug targets as they are implicated in
neurotransmission, cognition, memory, mood and circadian
cycle regulation, muscle, and broncho- and vasoconstriction.
However, for the desired mode of action, often a specific
selectivity or polypharmacological profile of the drug is needed
(see Figure 1 for drugs known to act on multiple GPCRs
discussed in this study). Among GPCRs, the aminergic family
is the most extensively covered by structural biology studies,
including crystal structures of 13 receptor subtypes and 40
different aminergic receptor−ligand complexes. Despite the
availability of such structural data, these structures still
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represent only a fraction of the large number of known
aminergic ligands (1−12 cocrystallized ligands vs 19−4758
ligands in ChEMBL9 per receptor, see Table 1). Furthermore,
the cocrystallized ligands in these complexes are chemically
similar to only 10% of all known active ligands of aminergic
receptors, rendering additional information necessary to
uncover their binding modes.10 The combination of crystal
structure information with analyses of ligand structure−activity
relationships (SAR), and receptor mutagenesis data can
provide complementary information to enrich the knowledge
on structural receptor−ligand information and to facilitate
computational binding mode prediction of chemically
dissimilar ligands as well.11
Site-directed mutagenesis (SDM) is a versatile and
frequently employed tool in pharmacological investigations
used to infer structural features of protein−ligand interactions.
GPCR research has especially benefited from the large body of
available mutational data.12 Mutation studies complement
structural information provided by crystal structures by
defining the roles and relative importance of residues involved
in binding, functional activity, and selectivity of a variety of
receptor−ligand combinations, and thus an integrated analysis
of these data is crucial.13 Much of the early mutational data on
GPCRs was collected in the TinyGRAP database,14 but today
the largest resource of GPCR sequence, structure, and
mutation data is the GPCR database (GPCRdb, http://
gpcrdb.org).12,15−17 The GPCRdb also features structure-
based sequence alignments18 that enable the identification of
structurally equivalent positions for large-scale analysis of data
related to GPCR sequence. This database is constantly being
improved by community contributions of manually curated
and annotated mutagenesis data sets. The Pocketome
database19 also contains information about single-point
mutations of crystallized proteins grouped by binding pocket
homology. These data sources provide valuable information for
medicinal chemists, molecular biologists, and computational
chemists for various types of analyses. Community-wide GPCR
structure modeling challenges (GPCR Dock 2008,20 2010,21
and 201322) have shown that the best models could be
constructed by careful incorporation of mutation and SAR data
relating to ligand binding.23−25 However, a receptor family
wide analysis is required to provide insights on a structural
chemogenomics level and to complement available data in
order to fill gaps in mutant−ligand matrices for single
receptors. Such an analysis has been carried out for adenosine
receptors13 but not yet for the aminergic GPCR family.
Although a large body of mutagenesis data has already been
accumulated for the aminergic GPCRs, this information is still
sparse considering all unexplored combinations of receptors,
amino acid positions, mutations, and ligands. Through an
exhaustive database and literature search, 6692 mutational data
points were collected for 34 aminergic GPCR subtypes of eight
species. This review provides a systematic overview of all
mutation data of aminergic GPCRs, mapped on all currently
available crystal structure information. The mutation data are
described per binding pocket region observed in the different
GPCR crystal structures: amine and major pocket, minor
pocket, and extracellular vestibule (ECV) and are discussed in
relation to ligand chemotypes and SAR (where sufficient
ligands are available). This integrated analysis and presentation
provides new insights into receptor regions more or less well
characterized and allows translation of mutation data between
aminergic receptors. To bridge the gap between crystal
structures and mutation data for ligands for which no binding
mode information is available, we have combined docking and
interaction fingerprint (IFP) scoring approaches26 to map the
mutation data on validated binding modes of the ligands
involved in mutation studies in complexes with crystallized
aminergic receptors. We hypothesized that mutational effects
may be transferable between ligands of similar binding modes
in the increasingly complex cases of (i) the same receptor
subtype, (ii) between receptor subtypes in the same subfamily
with X-ray structures, or (iii) using homology models. By
mapping the mutation effects on structure-based generic amino
acid positions, we were able to identify interesting mutations
that are missing from the current mutational repertoire of
aminergic GPCR investigations and show that prediction of
mutation effects is feasible, albeit with limitations.
2. MUTATIONAL DATA COLLECTION AND ANALYSIS
2.1. Mutational Data Collection. Data from equilibrium
ligand binding experiments (saturation or displacement) on
single amino acid mutants of 34 aminergic receptors were
collected using references from the TinyGRAP database,14
GPCRdb,12,15−17 and PubMed search (with keywords
“mutant(s)”, “mutation(s)”, “mutagenesis”, “site-directed”,
and the respective receptor names). For the adrenergic α2C
and the trace amine TAAR1 receptors, no such data was found.
For the sake of interpretability, our analysis: i) primarily
focused on the annotation of the effects of single residue
mutations on ligand binding affinity; ii) did not consider the
effects of multiple simultaneous (double, triple, etc.)
mutations; iii) did not systematically annotate mutational
Figure 1. Heat map of bioactivity profiles of multiaminergic GPCR
drugs (compounds in rows with at least three activity values including
KD, Ki, IC50, and EC50 at aminergic receptors in ChEMBL which have
mutation data discussed in this paper) at all aminergic GPCRs (in
columns). Heat map colors run from red (pAct = 13) to white (no
measured activity, pAct = 0), no measurement is shown as gray cells.
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.8b00836
J. Med. Chem. 2019, 62, 3784−3839
3785
effects on functional activity, but includes a description of
similarities and differences between mutational effects on
functional activity and binding affinity (e.g., section 8.5).
2.2. Mutational Data Annotation. The mutational effects
on ligand binding were manually annotated in the mutation
data submission format developed by GPCRdb,12,15−17
including mutation position and type, ligand name and
identifier, assay type and radioligand, mutational effect on
ligand binding (expressed as wild-type and mutant ligand
binding affinity or inhibitory constant, or fold effect, or
qualitative effect), and, if available, receptor expression data
(expressed as wild-type and mutant surface expression or fold
expression, or qualitative effect). The collected data set was
deposited in Zenodo27 and uploaded to GPCRdb.12,15−17
Statistics of the data set are shown in Figure 2 and Table 1. All
mutational effects were then converted to mutant activity/
wild-type activity and were discretized into four classes: <0.3
(increased), 0.3−3 (no effect), 3−10 (decreased), >10
(abolished). If more data points were available for a given
point mutation−ligand pair, the geometric mean of the fold
effect value was taken. To facilitate systematic comparison of
structurally equivalent positions over multiple receptor
subtypes, receptor residue numbers were annotated by their
UniProt28 numbers (for specific receptors) as well as their
structure-based generic class A GPCR (Ballesteros−Wein-
stein29) residue number (as superscript).18 This generic
GPCRdb residue numbering scheme accounts for bulges and
constrictions in the transmembrane helices, and defines residue
numbers by their helix number, an “×” separator, and the
residue number in the helix (50 denotes the most conserved
residue).18 D3×32, for example, is the characteristic aspartate in
aminergic receptors, which is located in TM3, 18 positions
before the most conserved residue in TM3 (R3×50). Bulges are
denoted by an additional number after the preceding residue
number, such as 5×461, and constrictions are skipped numbers
relative to a normal helix. The most conserved residues of
ECL1 and ECL2 are denoted as W23×50 and C45×50,
respectively. As this review focuses on mutation effects on
ligand binding, a consensus binding site was defined as a
collection of residues annotated as ligand contacting residues
in any aminergic receptor crystal structure by GPCRdb (see
Figure 3).15−17 This resulted in the following set of generic
residue positions:
• amine pocket: 3×32, 3×36, 6×48, 6×51, 7×38, 7×42
• major pocket: 3×33, 3×37, 3×40, 4×56, 4×57, 5×39,
5×40, 5×43, 5×44, 5×461, 5×47, 6×44, 6×52, 6×55,
6×56
• minor pocket: 2×53, 2×56, 2×59, 2×60, 3×28, 3×29,
7×34, 7×35, 7×39, 7×41
• extracellular vestibule: 2×63, 2×64, 23×50, 45×50,
45×51, 45×52, 5×36, 5×37, 6×58, 6×59, 7×31.
Data points were annotated using the generic numbering
system and selected for the consensus binding pocket, which
allowed construction of heat maps of the mutation effects
across receptor subtypes and even across the whole aminergic
receptor family. Data analysis was carried out using a
Figure 2. Structural and mutation data available for aminergic GPCRs. (A) Full GPCR phylogenetic tree color coded according to the number of
unique crystal structure complexes. (B,C) The aminergic branch of the GPCR phylogenetic tree with mutation data statistics, circle sizes, and color
coding according to the different data types. (B) Number of active ligands in ChEMBL (pAct > 6, activity types considered: EC50, IC50, KD, Ki).
(C) Number of unique mutant−ligand combinations in mutation studies.
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customizable KNIME workflow, making use of the 3D-e-
Chem41 ,42 KNIME43 nodes communicat ing with
GPCRdb.12,15−17 This workflow fetches the available mutation
data and the mapping between UniProt and generic numbering
for aminergic GPCRs from GPCRdb, calculates the fold effect
and binning of the data, and then constructs the heat maps
after customized data filters are applied. The KNIME workflow
Figure 3. (A) Location of the 42 consensus binding site amino acid residues analyzed in the present paper, spheres indicating Cα positions, the
structure depicted is 5-HT2B 4IB4. (B) Binding site amino acids involved in mutation studies in serotonin, muscarinic acetylcholine, adrenergic,
dopamine, and histamine receptors, the structures depicted are 5-HT2B (PDB: 4IB4
31), M2 (PDB: 4MQT
34), β2 (PDB: 2RH
12), D3 (PDB:
3PBL38), and H1 (PDB: 3RZE
40). (C) Location of ligand binding pockets (amine pocket, minor pocket, major pocket, extracellular vestibule) in













40). (D) Ligand binding site residue alignment of crystallized aminergic GPCRs. Generic
GPCRdb residue numbers18 are colored according to the binding pockets defined in panel A, and residue positions in contact with a ligand in any
crystal structure of the given receptor are marked gray.
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and workflow scheme are included in the Supporting
Information.
2.3. Mutation Data Analysis. The obtained collection of
mutational data points was analyzed to provide insights into
the extent of mutational coverage of all receptors, amino acid
positions, and ligands. Altogether, 6692 data points were
collected for the 34 aminergic receptor subtypes. Data for the
human orthologue was available for all of these receptors. For
12 receptors, data for one additional species and for eight
receptors data for two additional species could also be
incorporated (see Table 1). Although bioactivity data or
mutational effects might vary for different species, in this study
these data have been combined because crystal structures used
for docking for solely one species per receptor were available.
The distribution of the amount of information available for
particular receptor subtypes (Table 1) showed that the highest
Table 1. Overview of the Collected Aminergic GPCR Mutation Data Set
aReceptor orthologues: h = human, r = rat, m = mouse, d = dog, g = guinea pig, p = pig, ham = hamster, mac = macaque. Number of active ligands
in ChEMBL (pAct > 6, activity types considered: EC50, IC50, KD, Ki) determined for the human orthologue.
bNumber of mutants defined as the
number of unique combinations of the generic position number from GPCRdb18 (or UniProt number when that is not defined) and the amino acid
type in the mutant, in brackets the number of mutants are aggregated for the orthologues; note that in this case the wild-type residues may differ.
cNumber of positions defined as the number of unique generic position numbers from GPCRdb18 (or UniProt numbers when that is not defined).
dRedundancy defined as the percentage of data points exceeding the number of unique mutant−ligand combinations. eCompleteness defined as the
number of unique mutant−ligand combinations divided by the product of the number of mutants and the number of ligands for that receptor.
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.8b00836
J. Med. Chem. 2019, 62, 3784−3839
3788
number of data points was available for muscarinic acetylcho-
line receptors (2333 data points), with the M1R providing the
highest contribution to this number (1214 data points). The
number of mutants these data correspond to was assessed in
two ways. First, mutants were defined by the receptor, species,
sequence-specific position, and introduced amino acid. Second,
mutants were defined by receptor, generic position (from
GPCRdb),18 and introduced amino acid. The former allowed
for simple summation of mutants in subfamilies and the whole
data set, while the latter allows for the assessment of the
number of different types of mutations carried out across
receptor subtypes and subfamilies. From the comparison of the
two numbers, it can be seen that the same mutations for
different species have rarely been introduced (0−14% overlap).
From the inspection of the original publications, it is also seen
that research groups often work only with a single species
throughout several publications and the overlap between
efforts of different groups working on different species is
understandably small. However, often exactly those positions
are mutated that make up the difference between sequences of
different species. For the different aminergic receptor
subfamilies, 16−42% of the mutations defined by generic
position have been performed on more than one subtype. Also,
the number of generic positions regardless of introduced
amino acid were enumerated. For most subtypes, the average
number of mutations per position was between one and two,
but for M5R, for example, this ratio was 3.6. For the whole data
set, the average number of introduced amino acids was 2.3. In
the whole set, mutational data for 316 unique positions were
found, accounting for 71% of the average length of the
aminergic receptor sequences. The number of unique ligands
was assessed based on the unique ligand identifiers in the data
set (ChEMBL ID,9 PubChem CID,44 FASTA sequence, or
SMILES string). The overlap between ligand sets of the
different subtypes within subfamilies was 30−38% for the
serotonin, muscarinic, adrenergic, and dopamine receptors, but
it was only 6% for histamine receptors (histamine, thioper-
amide, and clobenpropit were used for multiple receptors).
The number of mutants assessed in both described ways and
the number of unique ligands were combined to obtain the
number of unique mutant-ligand combinations. A ratio of this
number and the number of data points allowed for the
estimation of the redundancy of data points for each subtype
and subfamily, which ranged from 0% to 38% (for the α2A
receptor). These redundant data points either come from the
same publication (66%) being different data types (radioligand
KD and competition Ki) or multiple data points for the same
measurement (e.g., low and high-affinity receptor states), or
they come from different publications (34%), being again
different data types or using a different radioligand. The ratio
of the number of unique mutant−ligand combinations and the
product of the number of mutants and ligands was also
calculated, that is, what percent of the heat maps for each
receptor subtype is filled with known mutation effect data,
which we call the completeness of the data subsets. Except for
some receptors with very few data points, the completeness
varied from 8% to 76%. When completeness for the subfamilies
was assessed, this dropped to 3−7% because of the low overlap
of the employed mutations for the different subtypes. Finally,
this further drops to about 1% completeness when the whole
data set is considered, meaning that the full GPCR mutation
heat map is very sparse, with small well-filled areas and large
empty areas.
In the whole data set of 5445 unique receptor mutation−
ligand combinations, there are 862 mutant−ligand combina-
tions for which multiple data points are available. Out of these,
230 cases (116 in the binding site and 114 in another region of
the receptor) covered mutational effects across different classes
(fold <0.3 increased effect, 0.3−3 no effect, 3−10 decreased
effect, >10 lost effect). Only 47 mutant−ligand combinations
cover nonadjacent classes. The highest discrepancy is observed
for acetylcholine and N-methylscopolamine (NMS) in human
and rat M1 receptors, for which both increased an decreased
effects are reported for specific mutant−ligand combinations.
The highest number of mutant−ligand combinations with
multiple data points were observed for human M1 (117 of
which 67 assigned to different classes), human M4 (104 of
which 1 in different classes), and rat D2 (93 of which 32 in
different classes) receptors. Uncertain data points with
multiple class effects are indicated with a cross in the
heatmaps, but the geometric mean of all data is used for
depiction. Data discrepancy may originate from several factors:
intra- and interlaboratory variation in assay conditions,
different radioligands used, and different receptor constructs
used. For some receptor mutants, different effects were
reported for different radioligands. For example, F1854×61A
and S3446×55A mutants of human 5-HT1B result in a 6-fold
decrease and a 4-fold increase of 5-HT affinity in [3H]5-HT
radioligand displacement assays but do not affect 5-HT affinity
in [3H]GR125743 displacement studies.45,46 In [3H]5-CT and
[3H]5-HT radioligand displacement studies, the T3627×38N
mutant of 5-HT1B caused the same 8-fold decrease of
methysergide affinity but resulted in 6- vs 15-fold decrease in
sumatriptan affinity, respectively.47,48 The S1965×38L mutant of
5-HT1D resulted in 3- vs 7-fold decrease in ketanserin binding
in [3H]5-CT and [3H]GR125744 displacement studies,
respectively.49 Different radioligands gave similar mutational
effects for rat 5-HT2A ([
125I]DOI, [3H]ketanserin),50 rat 5-
HT2C ([
3H]5-HT, [3H]mesulergine), human muscarinic M1
([3H]QNB, [3H]NMS),51−53 and human adrenergic α1A
studies ([3H]prazosin, [3H]KMD-3213).54
The residues involved in mutational data points were labeled
either as ligand-contacting or noncontacting residues. In total
49% of the whole mutational effect data set (3338 data points)
covers residues that are involved in protein−ligand interactions
in currently available crystal structures of the corresponding
aminergic receptor subfamilies (Figure 3). It should be noted
however, that at the time of the original publications, these
positions were mostly hypothesized. Using the consensus
binding pocket definition, 55% of the data set was classified as
representing protein−ligand interaction data. The most
mutated amino acid positions outside the ligand binding
pocket were 6×34 in the intracellular end of TM6 with 369
data points, then 2×50, 3×49, and 3×50 with over a hundred
data points each (section 8.4). The number of known crystal
contacts is 305 (gray cells in Figure 3), of which 153 (50%)
have already been investigated in mutational studies. No
observed ligand binding amino acid positions have yet been
mutated in the 5-HT1E/1F and H2 receptors, and only one of
those positions have been mutated for the 5-HT1D, α1D, and β3
receptors. The obtained mutagenesis data were mapped to the
amino acid residues making contacts in crystallized aminergic
GPCRs, presented in the form of heat maps (Figures 5, 8, 11,
14, 17), and the ligands involved in mutation studies are shown
in Figures 6, 9, 12, 15, and 18. The color codes in the heat
maps refer to the fold mutation effects, that is, the ratio of Ki
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MUT/Ki WT (wild type) below 0.3 (cyan), between 0.3 and 3
(blue), between 3 and 10 (yellow), and above 10 (red). For
selected examples, mutation effects were mapped on structures
including a cocrystallized ligand (or a very similar ligand), the
modeled binding mode of the endogenous ligand, and the
modeled binding mode of a drug-like ligand with relative high
number of mutation data points for each receptor subfamily
(Figures 7, 10, 13, 16, 19).
2.4. Structure-Based Extrapolation of Mutational
Data. Opportunities to map and extrapolate mutational data
across different receptor−ligand complexes were assessed by
combining mutation data mining with structural interaction
fingerprint based binding mode prediction based on aminergic
receptor crystal structures.
2.4.1. Docking. All available crystal structures for aminergic
GPCRs were fetched from the PDB database55 and manually
cleaned from additional entities so that only the protein and
the cocrystallized ligand remained. Sets of ligands used in
mutational studies associated with particular receptor subtypes
and species were prepared for docking: their possible
tautomeric and protonation states were calculated with the
Calculator56 from the ChemAxon package. Three-dimensional
conformations of the structures were then generated with the
use of Molecular Networks’ Corina57 software. Docking was
performed using PLANTS58,59 (version 1.2), and for each
ligand 25 poses were produced (speed setting 2) and were
scored using the ChemPLP scoring function. The binding
pockets were defined in a consensus way taking into account
all amino acid positions contacting any cocrystallized ligands in
the aminergic GPCR crystal structures within 5 Å. This
selection resulted in 53 amino acid positions for all considered
targets (1×35, 1×39, 2×53, 2×551, 2×56, 2×59−64, 3×25,
3×28, 3×29, 3×32, 3×33, 3×36, 3×37, 3×40, 4×56, 4×57,
4×59, 4×60, 45×50−52, 5×39−45, 5×461, 5×47, 6×44,
6×48, 6×51, 6×52, 6×54−56, 6×58, 6×59, 7×30, 7×31,
7×33−35, 7×38, 7×39, 7×41, 7×42 in generic GPCRdb
numbering18). For muscarinic receptors, orthosteric ligands
were distinguished from allosteric ones, and additional docking
to the allosteric site was performed based on amino acids
contacting the allosteric ligand in the M2 structure with PDB
4MQT.34 All obtained ligand−receptor complexes were
represented using interaction fingerprints (IFP),26 with bits
characterizing interaction of ligands with each of the amino
acids of the binding pocket (7 bits per position: hydrophobic,
aromatic (2 bits), H-bond (2 bits), ionic (2 bits)) allowing for
a fingerprint of 371 bits. The poses that did not possess a
required H-bond or ionic interaction with the conserved
aspartate D3×32 in aminergic receptors were filtered out, and
the remaining ones were ranked according to descending
Tanimoto coefficient (Tc) values to the reference IFP
(calculated for the ligand cocrystallized with particular crystal
structure). Thereafter, IFPs of ligands with a Tc value over a
certain cutoff were used in a second round as reference IFPs,
and poses with IFP similarity to any of these reference IFPs
above the same Tc value cutoff were also selected (the grid
search-based optimization of the Tc value cutoff for the
procedure was carried out in the range of 0.6−0.9 with a step
of 0.05; the lower bound was set on the basis of generally the
Figure 4. Structural receptor−ligand interaction fingerprint (IFP) similarity based receptor mutation data mapping flowchart for the prediction of
receptor mutation effects. (a) PLANTS58,59 docking; (b) structural interaction fingerprint (IFP) analysis.26
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accepted cutoff for overall pose similarity).26 This two-step
pose selection protocol allowed identification of plausible
poses for most docked orthosteric ligands even when the IFP
similarity to the cocrystallized ligand was lower than the
predefined cutoff due to, e.g., size difference of the ligands.
After the sensitivity assessment part in the subtype specific
studies, an IFP similarity cutoff of 0.7 was used for all steps
(Figure 4).
2.4.2. Prediction of Mutational Effects. After construction
of the mutation effect heat maps for all receptor subtypes,
retrospective studies were conducted using leave-one-out
experiments, in which all data points were separately removed
and predicted from the remaining data set. From each
mutant−ligand pair, the examined ligand was assigned to the
mutational effect class of the compound which had a known
effect at the examined mutant and to which it had the highest
IFP similarity unless the similarity coefficient was lower than
the assigned similarity threshold (Figure 4). The prediction
power of the protocol was evaluated by accuracy expressed as
the ratio of the number of correct mutational effect class
predictions and the number of predictions plus the number of
cases where a prediction could not be made (blank fields) due
to lack of ligands with a known mutational effect and IFP
similarity above the imposed threshold. Leave-one-out
accuracy of the method was assessed, and mutational effects
were prospectively predicted in the same manner as for the
retrospective evaluation.
3. SEROTONIN RECEPTORS
3.1. Structural Serotonin Receptor−Ligand Interac-
tions. Serotonin receptors are activated by the small
neurotransmitter serotonin or 5-hydroxytryptamine (5-HT).
In humans, there are 12 5-HT receptor subtypes, of which
three (5-HT1B, 5-HT2B, and 5-HT2C) have currently been
crystallized.30,31,60,61 The ergotamine and dihydroergotamine
bound 5-HT1B (PDB: 4IAR, 4IAQ
30), the ergotamine and
lysergic acid diethylamide (LSD) bound 5-HT2B (PDB:
4IB4,31 4NC3,60 5TUD,62 5TVN61), and the ergotamine
bound 5-HT2C (PDB: 6BQG
32) crystal structures show a
conserved binding mode of the ergoline scaffold in the
orthosteric pocket, covering residues in the amine pocket
(D3×32, C/S3×36, W6×48, F6×51, T/V7×38, Y7×42) and major
pocket (I/V3×33, T3×37, I3×40, I/V4×56, F/Y5×39, T/M/V5×40, G/
S5×43, S/T5×44, A5×461, F6×52, S/N6×55). The butterfly shaped
diaromatic scaffolds of methiothepin in 5-HT1B (PDB:
5V5463) and ritanserin in 5-HT2C (PDB: 6BQH
32) mainly
contact the same residues, only the p-fluorophenyl moiety of
ritanserin reaches into a deeper pocket additionally forming
aromatic interactions with F2235×47 and F3206×44 in the major
pocket in 5-HT2C. The interaction patterns with different
residues targeted in the minor pocket and extracellular
vestibule (A/S2×60, Y/T/A2×63, W3×28, L/I3×29, V45×51, V/
L45×52, M/L/S6×58, P/V6×59, L/Q/E7×31, F/L7×34, D/E/N7×35)
of 5-HT1B, 5-HT2B, and 5-HT2C by the tripeptide appendages
of cocrystallized ergotamine and dihydroergotamine, the
thiazolopyrimidinon appendage of ritanserin, as well as other
dualsteric ligands (i.e., ligands interacting with both the
orthosteric binding pocket and the extracellular vestibule),
determine the ligand-dependent structure−affinity, −function,
and −selectivity relationships of serotonin receptors.64
Serotonin receptor crystal structures are generally similar to
each other per subtype, but there is some variation among
subtypes seen in the extracellular tips of TM helices and ECL2
conformation. The average heavy atom RMSD for 5-HT1B, 5-
HT2B, and 5-HT2C receptor subtypes are 1.3, 0.9, and 1.4 Å,
respectively. The average backbone RMSD for these subtypes
are 0.8, 0.5, and 1.0 Å, respectively. The average backbone
RMSD for all 5-HT receptors is 1.2 Å, with the largest
difference of 1.9 Å between the methiothepin-bound 5-HT1B
and the LSD-bound 5-HT2B (Figures 3, 7, 20). In this case, the
extracellular tips of helices TM4−7 are shifted about 2−2.5 Å
relative to each other. The structures with ergoline derivatives
show a conserved binding mode of the ergoline scaffold, only
LSD is shifted 1.5 Å higher in the binding site relative to the
other ligands. The upper aromatic moieties of methiothepin
and ritanserin overlap with that of the ergoline scaffold, and
their lower aromatic moiety reaches further toward the
hydrophobic core of the receptors, facilitated by a rotamer
change of I3×40. In the ECV, the benzyl appendage of
ergotamine and dihydroergotamine adopts different orienta-
tions in 5-HT1B/2B due to divergent amino acids T/M
5×40 and
M/L6×58. The ECV appendage of ritanserin is shifted toward
TM7 relative to ergotamine due to ECL2 protruding more
toward the binding site. In the amine pocket, D3×32 forms an
ionic interaction with the amine group of basic ligands
including tryptamine derivatives, phenylethylamine derivatives,
and arylpiperazines. Residues C/S3×36 and Y7×42 stabilize the
conformation of D3×32 and residues W6×48 and F6×51 form
cation−π interaction with basic ligands. These findings are
consistent with mutation studies (section 3.3.1) and SAR
studies showing the essential role of the cationic properties of
the amine group of ergoline ligands and other serotonin
receptor ligands. The ergoline scaffold of the cocrystallized
ligands ergotamine, dihydroergotamine, and LSD, and the
diaromatic scaffolds of methiothepin and ritanserin, make
hydrophobic interactions with I/V3×33, I4×56, F5×47, F6×44, F6×51,
F6×52, F/Y5×39, and T/M5×40 and form H-bond interactions
with T3×37 or the backbone carbonyl of G/S5×43 in the major
pocket between TM3−6. Mutation studies demonstrate the
important role of these hydrophobic and polar residues
(section 3.3.2) and SAR studies demonstrate the preference
of serotonin receptors for ligands with aromatic moieties
substituted optionally with a polar H-bond interaction
functionality, mimicking the 5-hydroxy-indole group of the
endogenous ligand. In 5-HT6, the mutation of S/N
6×55
underlines the important role of this residue in recognizing
prototypical sulfonamide ligands, including SB258585,
CHEMBL1085617 and CHEMBL1086326. In the minor
pocket and extracellular vestibule, the tripeptidic appendage
of the cocrystallized ergoline ligands forms H-bonds with the
backbone of V/L45×52 and other polar residues such as Y/
T2×63, L/Q7×31, and D/E7×35 are available for polar interactions
with appendages of dualsteric ligands including ketanserin,
buspirone, ipsapirone, and risperidone. However, such
mutant−ligand combinations have not yet been investigated
experimentally.
3.2. Chemical Space of Serotonin Receptor Ligands
in Crystal Structures and Mutation Studies. The
cocrystallized serotonin receptor agonists ergotamine (44
mutants, Figure 7), dihydroergotamine (1 mutant), LSD (50
mutants), the antagonists methiothepin (24 mutants), and
ritanserin (9 mutants), as well as the endogenous 5-HT (138
mutants, Figure 7) have been extensively investigated in
mutation studies of serotonin receptors 5-HT1A/1B/2A/2B/2C/6/7
(Figure 5) covering 30 different residues in total, of which 24
are within the binding site as observed in serotonin receptor
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crystal structures (Figure 3).30 Sixteen (11%) of the ligands
investigated in mutation studies are chemically similar (defined
throughout this paper as having a MACCS65 Tanimoto
similarity ≥0.8 or an ECFP-466 Tanimoto similarity ≥0.4)
and 20 (14%) are pharmacophorically similar (ROCS67
ComboScore ≥1.5) to any of the cocrystallized ligands (Figure
6). Nine ligands investigated in serotonin receptor mutation
studies contain the endogenous 5-hydroxytryptamine scaffold,
and 31 further ligands contain the tryptamine substructure that
is also part of the ergoline scaffold of the cocrystallized ligands.
5-Hydroxytryptamine and other tryptamine agonists cover 176
(20%) and 270 (31%) ligand mutant combinations,
respectively. Methoxyphenyl-ethanamines (including mesca-
line analogues DOM, DOB, DOI, and 2,4- and 2,5-
dimethoxyphenyl-ethanamines) and aminergic sulfonamides
(L-694,247 and SB269970) have been investigated at 146
ligand mutant combinations in total (17%). Most of these
compounds do not share 2D chemical or 3D shape/
pharmacophore-based similarity with cocrystallized serotonin
receptor ligands but represent combined ligand and receptor
SAR data sets that provide detailed information on the
structural determinants of serotonin receptor binding. More-
over, 14 ligands are chemically similar to cocrystallized ligands
in adrenergic β1/2 complexes (section 5), including antagonist
methoxyphenyl-ethanamines, iodocyanopindolol, penbutolol,
alprenolol, propranolol, pindolol, and labetalol.47,68−72 The
serotonin receptor agonists cisapride and zacopride are similar
to cocrystallized nemonapride39 in dopamine D4, and
risperidone37 is cocrystallized in dopamine D2 (section 6).
The serotonin receptor antagonist/inverse agonist amitripty-
line is furthermore similar to cocrystallized doxepin in the H1
crystal structure40 (section 7), whereas the serotonin receptor
agonists MCPP, TFMPP, quizapine, and MK-121 are similar
to the cocrystallized fragment-like piperazine ligands of the β1
adrenergic receptor (section 5).73 Several nonselective
aminergic receptor ligands including clozapine, spiperone,
ketanserin, chlorpromazine, lisuride, and haloperidol have been
investigated altogether at 44 different serotonin receptor
mutants as well as mutants at other receptor subfamilies. For
example, clozapine has been investigated in serotonin,
muscarinic, dopamine, and histamine receptor mutation
studies, providing insights into the receptor specific determi-
nants of binding of these ligands by different aminergic
GPCRs.
3.3. Structural Determinants of Serotonin Receptor−
Ligand Interactions. 3.3.1. Amine and Major Pocket
Mutations in Serotonin Receptors. Mutation of conserved
D3×32 to nonacidic residues (D3×32A/N/Q) has been shown to
diminish binding of 12 cationic ligands to three different
serotonin receptors, including 5-HT (5-HT1A, 5-HT2A 5-HT4),
LSD (5-HT4), gramine (5-HT1A), DMT (5-HT1A), DOI (5-
HT2A), ketanserin (5-HT2A, Figure 7), mianserin (5-HT2A),
spiperone (5-HT2A), ML10302 (5-HT4), ML10375 (5-HT4),
RO116-1148 (5-HT4), and CHEMBL1086326 (5-
HT6).
68,74−81 The D1553×32E mutation conserving the acidic
feature does not significantly affect rat 5-HT2A binding affinity
of the agonists 5-HT and gramine and the antagonist
spiperone, indicating that an ionic interaction with the anionic
carboxylate group of D1553×32 is required and sufficient for
ligand binding.77 The D1063×32A mutant diminishes 5-HT6
binding affinity for the basic sulfonyl-tetrahydronaphtalene
amines CHEMBL1085617, CHEMBL1086326, and
CHEMBL10825037 but does not affect binding of the neutral
amide analogues CHEMBL1082508 and CHEMBL1087777,
confirming the important role of the cationic amine moieties
on the ligand side and their interaction with the anionic D3×32
residue.80 5-HT1A affinity of the partial agonist pindolol is not
affected by the D1163×32N mutant but is decreased by the
N7×38V mutant,68−70 indicating that this residue is an
important interaction partner for the ethanolamine moiety of
pindolol, consistent with the binding mode of pindolol and
cyanopindolol in β1 adrenergic and β2 adrenergic receptor
crystal structures (section 5.1). The binding affinity of
antagonist GR113808 for 5-HT4 is not affected by the
D1003×32A or D1003×32N mutants but is significantly
decreased by the Y3027×42F mutant. The same mutant
decreases the affinity of RS395604, which shares a
piperidine-ethyl-sulfonamide substructure with GR113808
but does not affect binding of other ligands (ML11411,
RS100235), suggesting that Y3027×42 may play a role in an
alternative H-bond interaction network with the amine or
sulfonamide groups of GR113808 and RS395604.82,83 The
D1063×32A mutant increases the affinity of agonist BIMU8 for
5-HT6,
79 indicating that this mutation may create space for
binding of the bulky methyl-aza-bicyclo-octane moiety of this
ligand. Mutations of the conserved aromatic W6×48, F6×51, and
F6×52 residues lining the major pocket have variable, ligand-
dependent effects on binding to serotonin receptors.72,84
Whereas the affinity of ligands such as lisuride, mesulergine,
LY53857, 5-MeO-DMT, ketanserin, substituted dimethoxy-
phenyl-ethanamines (5-HT2A), LSD, and 5-HT (5-HT2B),
substituted sulfonyl-tetrahydronaphtalene amines (5-HT6) is
diminished by mutation of W6×48/F6×51/F6×52, the binding of
ligands ergotamine, LSD, 5-HT, RO116-1148 (5-HT1B, 5-
HT4), and ergotamine (5-HT2B) is not affected or is even
increased by mutation of these residues, respectively. The
V1363×33A mutation on the other face of the indole ring of the
cocrystallized ligands is detrimental to LSD and 5-HT binding
in 5-HT2B.
30 Mutation of the aromatic residue F/Y5×39 located
above V3×33 to alanine also reduces binding of LSD and 5-HT
to 5-HT2B but increases that of ergotamine.
30 Furthermore, the
M2185×40A mutation in 5-HT2B also increases binding of
ergotamine. It seems that despite the low nanomolar affinity of
ergotamine to 5-HT2B, the fit of the ergoline scaffold is not
optimal in this ligand−receptor complex. Furthermore, this
residue is phenylalanine in human and rat 5-HT6 receptors but
tyrosine in the mouse orthologue and the F1885×39Y mutation
reduces (while the Y1885×39F mutation increases) binding of
sulfonamide ligands Ro04-6790, SB258585, SB271046 and
SB357134, suggesting that this residue is not involved in H-
bonding with these ligands but probably forms only aromatic
interaction with their aromatic side chains.85 The important
role of T3×37 in providing an H-bonding partner to the indole
NH of 5-HT analogues is underlined by the mutation T3×37A
decreasing binding of 5-HT and LSD in 5-HT1B and 5-HT2B;
however, from the available crystal structures it is seen that this
role can also be fulfilled by the backbone carbonyl group of
G2215×43 in 5-HT2B.
30 Mutation of the residue 5×43 generally
does not have a pronounced effect on ligand binding except for
decreasing binding of 5-HT in 5-HT1A, suggesting an
alternative H-bond with 5-HT in this receptor. The
C1965×43A mutant of 5-HT4 furthermore increased binding
affinity of the partial agonist ML10302, possibly by enlarging
the binding site.68 Mutation of A5×461 of rat 5-HT2A, 5-HT2B,
and 5-HT2C to a serine or threonine increases binding of
several ergotamine analogues and 5-MT by providing an extra
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H-binding partner to the indole NH.50,86,87 N-Alkylated 5HT
analogues such as mesulergine, amesergide, N-isopropyltrypt-
amine, and N-isopropyl-5-MT on the other hand are reversely
affected by the A5×461S mutation. The reverse mutation
S2425×461A/N in human 5-HT2A and T196
5×461A in 5-HT6 is
detrimental to binding of 5-HT analogues but increases
binding of N-methylated mesulergine and methysergide.
Mutation studies indicate that the role of the small or polar
residue (A, E, N, or S) at position 6×55 is highly ligand-
dependent. The studies suggest that the amide side chain of
N6×55 forms important H-bond interactions with several
ligands, including the hydroxyl group of 5-HT (5-HT2B, 5-
HT4), the ether group of GR113808 (5-HT4), and the sulfonyl
moieties of CHEMBL1082508, CHEMBL1085617,
CHEMBL1086326, and SB258585 (5-HT6).
30,76,80,88 The
larger 5-HT analogues ergotamine and LSD (5-HT2B),
mesulergine (5-HT2C), and ML10302 (5-HT4) are less
dependent on interactions with N6×55. Mutation of the smaller
S3346×55 does not affect binding of the agonists ergotamine, 5-
HT, LSD, and the antagonist methiothepin to 5-HT1B, which is
Figure 5. Serotonin receptor mutation data.30,45−48,50,68−72,74−86,88,89,91−100 Data is shown for the consensus binding pocket defined using
structure-based generic position numbers from GPCRdb.18 Wild-type residues for the orthologues involved in mutation studies, and the mutant
residue are shown (note that only the mutations which have a data point shown in the table were actually carried out, the table is organized for
comparability among orthologues). Ligands are grouped similarly as in Figure 6. When multiple data points were available for the specific mutant−
ligand combination, the geometric mean of the fold effect values was used. Color coding: cyan, fold effect <0.3 (increased), 0.3−3 (no effect), 3−10
(decreased), >10 (abolished). Uncertain data points for which different mutational effect classes have been reported are marked with a cross.
Mutant numbers for each ligand and ligand numbers for each mutant are indicated on the right side and the bottom of the heat map, respectively.
The average fold effect (geometric mean) for each mutant is also shown at the bottom of the heat map. PDF and Excel versions of the heat map are
provided in the Supporting Information.
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consistent with the role of the longer amide side chain of N6×55
in binding of these ligands in 5-HT2B, 5-HT4, and 5-HT6.
30,45
The positive effect of the N3316×55A binding of 3′-halo-PAT
analogues to 5-HT2C is in line with a binding mode in which
the mutation allows these ligands to accommodate their apolar
phenyl ring in a subpocket defined by the smaller A3316×55
residue.88 Similarly, the S3346×55A mutation increases binding
of the agonist 8-OH-DPAT and the antagonist GR125743 to
5-HT1B,
45 possibly by enlarging the binding pocket for these
ligands. The S/T5×44A mutation has ligand-dependent effects,
it decreases binding of several 5-HT analogues but increases
that for DOI and CHEMBL584690 with large hydrophobic
appendages.
3.3.2. Minor Pocket and Extracellular Vestibule Mutations
in Serotonin Receptors. Ergotamine analogues possess a large
tripeptidic appendage extending into the extracellular vestibule
as well as ritanserin with its thiazolopyrimidinon appendage.
Several other dualsteric ligands including ketanserin, azapir-
ones, RS39604, and ML11411 also probably interact with the
minor pocket in serotonin receptors; however, not many
mutation data points are available for these ligands in
combination with mutants in the minor pocket (Figure 5).
The R3×28L mutation in 5-HT4 receptor reduces binding of the
antagonist RS-39604 and increases binding of the antagonist
ML11411, suggesting that R3×28 forms an important polar
interaction with the sulfonamide moiety of RS-39604, but does
not form an essential interaction polar interaction with
ML11411.82 The W1023×28F mutation in 5-HT6 reduces
binding of ergotamine, methysergide, and surprisingly of
several small 5-HT analogues as well.75 Also, the L3×29A
mutation reduces binding of the small 5-HT in 5-HT1B and 5-
HT2B but increases that of ergotamine to 5-HT2B by expanding
the minor pocket.30 The amino acids at positions 7×34 and
7×35 are highly variable among serotonin receptors, therefore,
it could be expected that mutation of these residues also has
variable effects on ligand binding. No pronounced effect of
these mutants is seen in 5-HT1B. The L362
7×34A mutant
surprisingly decreases binding of the small 5-HT, and the
E3637×35A mutant increases binding of ergotamine in 5-HT2B
while having no effect on the other ligand or on LSD
Figure 6. Serotonin receptor ligands used in mutation studies.30,45−48,50,68−72,74−86,88,89,91−100 Cocrystallized ligands in 5-HT1B, 5-HT2B, and 5-
HT2C structures are shown in red. Chemically similar (MACCS Tanimoto similarity ≥0.8 or ECFP-4 Tanimoto similarity ≥0.4) ligands to any of
the cocrystallized ligands in serotonin receptor crystal structures are indicated with orange background and chemically similar ligands to any
cocrystallized ligand in aminergic receptor crystal structures are indicated with a cyan background. Receptors with available mutation data for the
specific ligand are indicated along with the number of data points in parentheses. A PDF version of the figure is provided in the Supporting
Information.
Figure 7. Serotonin receptor ligand binding modes and associated mutation data. (A) 5-HT2B (PDB: 4IB4
31) with cocrystallized ergotamine,
mutation effects mapped on structure for 5-HT2B-ergotamine. (B) 5-HT2B (PDB: 5TVN
61) with docked 5-HT, mutation effects mapped on
structure for 5-HT2B-5-HT. (C) 5-HT2A homology model from GPCRdb with docked ketanserin, mutation effects mapped on structure for 5-
HT2A-ketanserin. See Figure 5 for color coding. Mutation effects for alanine mutants were used where available.
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binding.30 Even more interestingly, the E7×34R/T and R7×35V
mutants in 5-HT7 abolish binding of the agonist 5-CT and the
antagonist SB269970, although neither ligand is expected to
directly interact with these amino acids.83 The mutation of
positions 6×58 and 6×59 contacting the tripeptidic appendage
of ergotamine in crystal structures does not affect binding of
any probed ligand significantly; however, only six and three
data points are available, respectively. Finally, mutations in
ECL2 also have variable effects on ligand binding. Binding of
the antagonist ketanserin is negatively affected by the
L18945×51Q mutation in 5-HT1D, indicating that this residue
cannot form an H-bond with the appendage of ketanserin.89
The L20945×52A mutation decreases binding of the small 5-HT
but increases binding of ergotamine, while has no effect on
LSD in 5-HT2B.
30 These mutations have no effect on the tested
ligands in 5-HT1B. From the residues that do not have generic
structural numbers assigned, only the R102H mutant in the
ECL1 of guinea pig 5-HT1D has a significant positive effect on
the binding of the three PNU compounds, suggesting that the
isochroman-amide moiety forms a suboptimal interaction with
the arginine in the wild-type receptor.90
3.4. Structure-Based Extrapolation of Serotonin
Receptor Mutation Effects. Mutation data predictions
within the serotonin receptor family were performed for
human data for 5-HT1B and 5-HT2B receptors with 5-HT1B and
5-HT2B crystal structures (Figure 6). The number of data
points that could be used for extrapolation was 128 (20% of all
fields) for 5-HT1B and 63 (78% of all fields) for 5-HT2B points
available for 28 ligands at 23 mutants for the former serotonin
receptor subtype30,45−48,91,97,99 and just three compounds at
27 mutants for 5-HT2B.
30,78 Due to the relatively low protein−
ligand interaction fingerprint (IFP) similarities of ligands to the
cocrystallized compounds, no data points were retrieved in
retrospective studies for this group of receptors. Only the
cocrystallized ergotamine, dihydroergotamine ligands, and
metergoline could be docked to 5-HT1B with IFP similarity
>0.7, and the available mutation data for these ligands are
disjoint (Figure 7). Only ergotamine in 5-HT2B could be
docked with the same IFP similarity cutoff. For the same
reason, the protocol was only able to make further predictions
in prospective studies for ergotamine and dihydroergotamine
in 5-HT1B. The heat maps referring to the original data set
used for extrapolation, and the retrospective and prospective
predictions are provided in the Supporting Information.
4. MUSCARINIC ACETYLCHOLINE RECEPTOR
MUTATIONS
4.1. Structural Muscarinic Acetylcholine Receptor−
Ligand Interactions. Muscarinic acetylcholine receptors are
activated by the small neurotransmitter acetylcholine. In
humans, there are five muscarinic acetylcholine receptor
subtypes, of which M1, M2, M3, and M4 have been
crystallized,33−35,101,102 including tiotropium bound M1
(PDB: 5CXV33), iperoxo (PDB: 4MQS), iperoxo/
LY2119620 (PDB: 4MQT34) and 3-quinuclidinyl benzilate
(QNB) (PDB: 3UON101) bound M2, tiotropium (PDB:
4DAJ,35 4U14, 4U15) and N-methylscopolamine (NMS)
(PDB: 4U16102) bound M3, and tiotropium bound M4
(PDB: 5DSG33). The M2 receptor is unique among the
aminergic receptors as it is the only one crystallized in a ternary
complex with an orthosteric agonist (iperoxo) and a positive
allosteric modulator (LY2119620) bound in the extracellular
vestibule. These crystal structures show a conserved binding
mode of the quaternary amine scaffold of iperoxo, NMS, and
tiotropium and the protonated quinuclidine scaffold of QNB in
the orthosteric amine pocket, covering residues in the amine
pocket (D3×32, Y3×33, S3×36, W6×48, Y6×51, Y7×38, C7×41, Y7×42).
The aromatic and polar residues of the major pocket contact
the two aromatic rings of QNB and tiotropium and the single
cyclic moieties of iperoxo and NMS (Y3×33, N3×37, V3×40,
W4×57, T5×40, T5×43, A5×44, A5×461, F5×47, N6×52, V6×55). The
N6×52 residue forms concerted characteristic H-bonds with the
tertiary alcohol and ester groups of the muscarinic receptor
antagonists tiotropium, NMS, and QNB and a single H-bond
with the isoxazole ring of iperoxo and probably the carbonyl
group of acetylcholine. The cocrystallized orthosteric ligands in
the muscarinic receptors do not directly interact with residues
of the minor pocket and extracellular vestibule. A series of
tyrosine residues (Y3×33, Y6×51, Y7×38, Y7×42) closely pack
together to form a lid over the orthosteric binding pocket and
separating it from the observed allosteric pocket in M2. Some
dualsteric ligands that have high affinity for muscarinic
acetylcholine receptors such as aripiprazole or risperidone
extend toward these binding pockets; however, dualsteric
ligands are not commonly known among muscarinic ligands,
and to our knowledge they have not been studied in mutation
studies. The LY2119620 positive allosteric modulator, on the
other hand, binds entirely in the extracellular vestibule
contacting residues Y/F2×60, Y2×63, L/T/I2×64, W3×28, L3×29,
Y/F45×51, I45×52, S/N6×58, T6×59, E/N/K/D7×31, W7×34, and E/
T/N/S7×35 and furthermore E172 in ECL2 and A414 in ECL3
in M2. Other allosteric modulators, such as the permanently
charged gallamine and W84 or the multiply protonated TBPB,
also exploit the aromatic clusters found in the extracellular
vestibule to form cation−π interactions. Muscarinic acetylcho-
line receptor crystal structures are generally similar to each
other except for the agonist iperoxo bound structures (4MQS,
4MQT).34 The average heavy atom RMSD for M2, M3, and M4
receptor subtypes are 1.3, 0.7, and 0.4 Å, respectively. The
average backbone RMSD for these subtypes are 1.1, 0.5, and
0.2 Å, respectively. The average backbone RMSD for all
muscarinic acetylcholine receptors is 0.8 Å, with the largest
difference of 1.7 Å between the tiotropium-bound M1 and the
iperoxo and LY2119620-bound M2 (Figures 3, 10, 20). In this
case, the extracellular tip of TM5 is shifted about 2.5 Å
outward and the tips of TM6 and TM7 about 4 and 2.5 Å
inward in the agonist and PAM-bound structure relative to the
antagonist-bound structure. However, despite this large
rearrangement in the ECV by helix tilting, the extracellular
loop conformations are well conserved among all muscarinic
acetylcholine receptor subtypes. In the orthosteric ligands the
aromatic regions, the key acceptor, and the charged basic
center overlap almost perfectly among all muscarinic
acetylcholine receptor subtypes. For ECV-bound allosteric
ligands, however, there is only one available crystal structure,
comparison of allosteric ligand binding modes is thus not
possible. In the amine pocket, D3×32 forms an ionic interaction,
while residues Y3×33, W6×48, Y7×38, and Y7×42 form cation−π
interactions with the conserved tertiary and quaternary amine
moieties of muscarinic acetylcholine receptor ligands con-
sistent with mutation studies (section 4.3.1) and SAR studies,
showing the essential role of the cationic properties of the
amine groups of tropane, quiniclidine, 1-azabicyclo[2.2.1]-
heptane, piperidine, and piperazine containing ligands and
acetylcholine derivatives. Mutation data of these five residues
equivocally support their important role in ligand recognition.
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The bulky tropane and quinuclidine scaffolds of the cocrystal-
lized ligands tiotropium, QNB, and NMS also make hydro-
phobic interactions with the aforementioned aromatic residues.
The bis-phenyl and bis-tiophenyl moieties of QNB and
tiotropium form interactions in the major pocket with Y3×33,
V3×40, W4×57, A5×461, F5×47, W6×48, Y6×51, and V6×55. Mutation of
most of these hydrophobic residues greatly affects ligand
binding. N6×52 forms H-bond interactions with polar scaffold
substituents in the major pocket between TM3−6. The
importance of this single residue is underlined even by the
fact that 78 data points for 12 different mutants of this residue
are available. Taken together, mutation and SAR studies
demonstrate the preference of muscarinic acetylcholine
receptors for ligands with aromatic moieties substituted with
at least one polar H-bond interaction functionality, mimicking
the ester group of the endogenous acetylcholine or the
hydroxyacetate group of the cocrystallized ligands. In the
minor pocket and extracellular vestibule, the quaternary
ammonium or basic amine and aromatic groups of prototypical
muscarinic allosteric modulators (Figure 9) interact with
residues including Y/F2×60, Y2×63, L/T/I2×64, Y/F45×51, E/N/
K/D7×31, W7×34, and E/T/N/S7×35. Mutation of these residues
affect allosteric modulator binding but usually have little or no
effect on orthosteric ligands. Mutation of several other amino
acids in the minor pocket and extracellular vestibule had little
effect on all studied ligands.
4.2. Chemical Space of Muscarinic Acetylcholine
Receptor Ligands in Crystal Structures and Mutation
Studies. The cocrystallized muscarinic acetylcholine receptor
antagonists NMS (investigated in combination with 402
different mutants), QNB (135 mutants), and tiotropium (30
mutants) as well as the endogenous acetylcholine (279
mutants) have been extensively investigated in mutation
studies of all muscarinic acetylcholine receptors covering an
astounding 135 different residues in total (Figures 8, 9, and
10), including 38 residues that are lining the binding sites in
muscarinic receptor crystal structures (Figure 3). On the other
hand, cocrystallized ligands iperoxo and LY2119620 have not
been involved in mutational studies yet. The most similar
ligands to these are oxotremorine-M (with 32 mutants) and
LY2033298 (with 42 mutants, Figure 10). Twenty-four (23%)
of the ligands investigated in mutation studies are chemically
similar, and 41 (39%) are pharmacophorically similar to any of
the cocrystallized ligands (Figure 9), covering 626 (33%) and
809 (43%) ligand−mutant combinations, respectively. Quinu-
clidine derivatives (e.g., QNB, L-698,583, Ac-N-Me-Quin),
tropane (e.g., tiotropium, NMS, atropine, benztropine), and
tetra-alkyl ammonium containing agonists (e.g., iperoxo,
oxotremorine-M, acetylcholine analogues) have been inves-
tigated at 1038 ligand−mutant combinations in total (55%).
The antagonist pirenzepine and analogues UH-AH 37 and AF-
DX 116 and clozapine with N-desmethyl analogue (covering
178 different mutants in total) are examples of a ligand series
that do not share 2D chemical similarity with cocrystallized
muscarinic acetylcholine receptor ligands but that represent
combined ligand and receptor SAR data sets that provide
detailed information on the structural determinants of
muscarinic acetylcholine receptor binding. Allosteric modu-
lators, such as gallamine, W84 and the piperidine benzimida-
zolinones TBPB and VCP794, the N,N-dimethyl piperidine
VCP813, quinolinone analogues BQCA, benzoquinazolinone
12, AC-260584, and 77-LH-28-1, cover 200 mutant−ligand
combinations in total (11%). No ligands are chemically similar
to cocrystallized ligands in aminergic receptor complexes from
other families. However, the orthosteric ligands clozapine and
N-desmethylclozapine (altogether 25 mutants) are tricyclic
compounds similar to cocrystallized doxepin in the histamine
H1 crystal structure (section 7) and also show a high affinity
for the H1 receptor.
103 Clozapine has been investigated at three
muscarinic acetylcholine receptor mutants, as well as mutants
at other receptor subfamilies (in serotonin, dopamine, and
histamine receptor mutation studies), providing insights into
the receptor specific determinants of binding of this ligand by
different aminergic GPCRs (see section 9).104−107
4.3. Structural Determinants of Muscarinic Acetyl-
choline Receptor−Ligand Interactions. 4.3.1. Amine and
Major Pocket Mutations in Muscarinic Acetylcholine
Receptors. Mutation of conserved D3×32 to nonacidic residues
(D3×32N/A) has been shown to diminish muscarinic acetylcho-
line receptor binding affinity of almost all 38 tested ligands.
However, McN-A343 (hypothesized to be a mixed orthos-
teric−allosteric ligand108) and the arylacetylene oxymes are not
affected by the D1033×32N mutation in M2 and it even
increases the affinity of the allosteric modulator LY2033298
binding in the extracellular vestibule. The acidic D3×32E mutant
significantly decreases muscarinic acetylcholine receptor
affinity of 21 ligands (mostly quaternary amines, including
the agonists acetylcholine, carbachol, oxotremorine-M, and the
antagonist NMS) but does not significantly affect the affinity of
17 other ligands (mostly tertiary amines including the
antagonists QNB, atoprine, and arylene-ene oxime ana-
logues).33,51,109−114 These data indicate that both the ionic
character of the carboxylate group and the size of the D3×32
side chain are important for ligand binding, consistent with the
small, occluded pocket in particular for quaternary amine
moieties of tiotropium, NMS, and iperoxo in muscarinic
acetylcholine receptor crystal structures (Figure 3). The
S1202×56A mutant in rat M3 reduces affinity of N-
Figure 8. Muscarinic acetylcholine receptor mutation data.33,51−53,106,109−132,134−151 Data is shown for the consensus binding pocket defined using
structure-based generic position numbers from GPCRdb.18 Wild-type residues for the orthologues involved in mutation studies and the mutant
residue are shown (note that only the mutations which have a data point shown in the table were actually carried out, the table is organized for
comparability among orthologues). Ligands are grouped similarly as in Figure 9. When multiple data points were available for the specific mutant−
ligand combination, the geometric mean of the fold effect values was used. See Figure 5 for color coding. Mutant numbers for each ligand and
ligand numbers for each mutant are indicated in the right side and the bottom of the heat map, respectively. The average fold effect (geometric
mean) for each mutant is also shown at the bottom of the heat map. PDF and Excel versions of the heat map are provided in the Supporting
Information.
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methylscopolamine and trihexyphenidyl as this residue forms
an H-bond with D3×32, stabilizing the conformation of the key
acidic anchor. The S3×36 residue forms weak H-bond
interactions with the epoxide moiety of tiotropium and NMS
in the available muscarinic receptor crystal structures.
However, mutation of this residue to alanine does not have a
pronounced effect on binding of these and other similar
ligands, only on the binding of acetylcholine, carbachol,
Figure 9. Muscarinic acetylcholine receptor ligands used in mutation studies.33,51−53,106,109−132,134−151 Cocrystallized ligands in M1, M2, M3, and
M4 structures shown in red. Chemically similar ligands to any of the cocrystallized ligands in muscarinic acetylcholine receptor crystal structures
indicated with orange background, chemically similar ligands to any cocrystallized ligand in aminergic receptor crystal structures indicated with a
cyan background. Receptors with available mutation data for the specific ligand are indicated along with the number of data points in parentheses.
A PDF version of the figure is provided in the Supporting Information.
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clozapine, and N-desmethylclozapine.33,106,114−116 Mutation of
the conserved W4136×48 is detrimental to the binding of almost
all of 14 evaluated ligands but does not affect LY2033298
affinity to M4, consistent with the M2 crystal structure, which
showed that this allosteric modulator does not target the major
pocket.33,113,117,118 Y4397×38 and Y4437×42 form H-bonds with
D1123×32 to stabilize its conformation and participate in
creating an aromatic cage for the quaternary ammonium
ligands. Consistently, mutation of these residues to alanine
diminishes the binding of several tested orthosteric agonists
and antagonists (NMS, tiotropium, 4-DAMP, acetylcholine,
pirenzepine, himbacine),33,53,113,119,120 while mutation to
phenylalanine usually has a milder effect consistent with
maintaining the cation−π interactions.53,121,122 The effect on
allosteric modulators gallamine, methoctramine, LY2033298,
as well as BS-6181 lacking a positively charged group is either
nonsignificant or even increasing affinity. Y3×33 and Y6×51 along
with the above-mentioned residues form the tyrosine lid over
the orthosteric pocket and their mutation is generally
detrimental to orthosteric ligand binding. The Y3×33A mutation
is employed 33 times in the data set and 24 times it decreases
ligand binding. Clozapine, N-desmethylclozapine, and allos-
teric modulators VCP813, AC-42, AC-260584, McN-A343,
and LY2033298 are unaffected by this mutation.121−123 The
Y6×51A mutation is employed 58 times, out of which 40 times it
decreases or abolishes binding of the tested ligand. Again, this
mutation has no or even the opposite effect on five tested
allosteric modulators, it increases binding of 77-LH-28-1 and
TBPB in M1 and M2. Even the Y
6×51F mutant decreases ligand
binding in 26 of 39 cases, but the effect is generally smaller
than for the alanine mutant.121,122,124−126 The conserved N6×52
residue was identified early on as one of the residues crucial for
ligand binding in the muscarinic acetylcholine recep-
tors.113,123,124,127−129 It is mutated to 12 different amino
acids in a total of 78 mutant−ligand combinations, and in 66
out of these, it diminishes or abolishes ligand binding to the
M1, M2, M3, and M5 receptors. The N508
6×52A mutant of M3
increases binding affinity for Cpd7 in which the hydroxyacetate
scaffold is methylated and therefore the H-bond with N6×52 is
expected to be disrupted. The N3826×52A mutant increases
CDD-0034 binding affinity for M1, possibly because the
tetrahydropyrimidine warhead forms a very strong interaction
with D1053×32 and creates an unfavorable H-bond geometry
with N3826×52. However, for the CDD agonists, arecoline and
APE, the authors report a discrepancy between binding and
functional effects: while binding is not affected or even
increased by the mutation, receptor activation is diminished in
all cases, indicating that the H-bonding potential of N6×52 in
muscarinic receptors is required for the activation process.127
Mutation of the other residues forming the major binding
pocket has ligand-dependent effects. The N1173×37A mutant
decreases binding of acetylcholine, QNB, pilocarpine, and N-
desmethylclozapine but expectedly does not have any effect on
allosteric ligands.33,114,115,123,130 The V3×40A mutant decreases
binding of QNB, NMS, tiotropium, and N-desmethylclozapine
in M3/4 but increases binding of acetylcholine and pilocarpine
and also does not have an effect on allosteric modula-
tors.33,113−115,130 The W4×57A mutant abolishes binding of all
tested orthosteric ligands in M3/4 but does not have a
significant effect on the allosteric LY2033298.33,109,113,119,131
Interestingly, the T5×40A mutant located at the top of the
orthosteric binding pocket decreases binding of NMS,
carbachol, and acetylcholine in M1 and M4 but does not
have an effect on binding of these ligands to M2 and even
increases binding of QNB, hyoscyamine, and pilocarpine in
M2, indicating that this residue might have differential roles in
these receptors.109,121,122,126,131,132 Mutation of T5×43, A5×44,
and A5×461 has little effect on binding of the investigated
ligands in M1/2/3 except for the T234
5×43A mutant on the
agonists carbachol and acetylcholine in rat M3. The F
5×47A
mutant decreases the binding affinity of N-methylscopolamine
for M1 and M3, and the affinities of tiotropium and
tiotropoium analogues Cpd1, Cpd2 and Cpd9 for M3. In
contrast, the F5×47A mutant does not have a significant effect
on the binding of QNB and acetylcholine and even increases
binding of Cpd7 with the methylated hydroxyacetate
scaffold.113,117 This residue is located deep in the orthosteric
pocket and seems to affect more the ligands with only one
aromatic ring through stacking contacts. The V5116×55A/I
Figure 10. Muscarinic acetylcholine receptor ligand binding modes and associated mutation data. (A) M3 (PDB: 4U16
102) with cocrystallized
NMS, mutation effects mapped on structure for M3-NMS. (B) M1 (PDB: 5CXV
33) with docked acetylcholine, mutation effects mapped on
structure for M1-acetylcholine. (C) M4 homology model based on M2 as a template (PDB: 4MQT
34) with docked LY2033298, mutation effects
mapped on structure for M4-LY2033298. See Figure 5 for color coding. Mutation effects for alanine mutants were used where available.
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mutations in the major pocket of M3 have little effect on the
investigated ligands.113,132
4.3.2. Minor Pocket and Extracellular Vestibule Mutations
in Muscarinic Acetylcholine Receptors. From the current
crystal structures, the minor pocket in muscarinic acetylcholine
receptors seems to be inaccessible for small molecule ligands.
The tyrosine lid almost completely separates the orthosteric
binding site and the extracellular vestibule, and the only
connection between them in the available crystal structures is a
narrow channel at position 4 of the more extracellular
thiophene ring of tiotropium. However, for ligand access to
and egress from the binding pocket, the lid must be flexible,
and it cannot be ruled out that future crystal structures will
show alternative arrangements of these residues. Indeed, it has
been shown in long-scale molecular dynamics simulations that
these tyrosines often change rotameric states but that their
flexibility depends also on the quality of polar interactions
ligands form with other residues of the binding site, e.g.,
N6×52.113,133 As described, the above mutation of the tyrosine
lid residues have a detrimental effect on orthosteric ligand
binding but variable effect on allosteric modulators, in some
cases even increasing allosteric modulator binding and
cooperativity. In the extracellular vestibule, the Y2×60A
mutation somewhat reduces binding of several orthosteric
ligands such as QNB, atropine, and carbachol possibly through
affecting ligand-binding kinetics.33,51,109,116,134 Interestingly,
the binding of acetylcholine is reduced by this mutation in M1,
not affected in M2, and increased in M4.
33,52,116 The Y2×60A
mutation decreases M1 binding affinity of the allosteric
modulator Benzoquinolinone 12 and dualsteric ligands
TBPB, VCP974 and VCP813, but does not have a negative
effect on M1/M2 affinity for 77-LH-28-1, AC42, BQCA, and
M4 affinity for LY2033298 (despite the fact that the co-
crystallized analogue LY2119620 forms an H-bond with this
tyrosine).33,51,52,109,116,135 The Y2×63A mutation decreases the
M1 affinity for Benzoquinolinone 12, TBPB, VCP974 and 77-
LH-28-1, but does not affect M1 affinity for VCP813, and M4
affinity for LY203329.33,51−53,109 Mutation of the conserved
W23×50 in ECL1 to alanine or even phenylalanine is detrimental
to the binding of orthosteric ligands and also to methoctramine
in M1 and LY2033298 in M4 possibly due to altering receptor
dynamics or folding.33,53 The W3×28A/F mutation, which is in
a stacking interaction with Y2×60 and W23×50 in the crystal
structures, is detrimental to the binding of orthosteric ligands
but has variable effects on binding affinity of allosteric
m o d u l a t o r s a n d d u a l s t e r i c l i -
gands.33,51,53,106,109,114−116,123,130,131,135−137 The W3×28A muta-
tion increases the binding affinity of 77-LH-28-1, TBPB,
VCP794, AC-260584, and AC-42 in M1 and M2, which might
be the result of the increased conformational freedom and
accessibility of Y2×60. In M4, the mutation also decreases
binding of W84 and LY2033298. The L3×29A mutation
abolishes or decreases binding of tested orthosteric and
allosteric ligands as well.33,51,109,114−116,130 This residue is
located between W3×28 and I45×52 and is probably required for
correct packing of ECL2. Mutation of Y45×51 and I45×52 located
in ECL2, however, seems to have very selective effects on the
tested ligands.33,51,52,109,116,117,120,135,138,139 In 40 of 58
mutant−ligand combinations, these mutations do not show a
significant effect on ligand binding to muscarinic receptors.
However, the Y45×51A mutant abolishes binding of benzoqui-
nazolinone 12 and LY2033298 in M1/4 but increases that of
TBPB in M1.
51,52 The Y17745×51Q mutant furthermore
abolishes binding of W84 in M2.
138 The I45×52A mutant
increases binding of BQCA, 77-LH-28-1, VCP794, and
LY2033298 (possibly by increasing the size of the allosteric
binding site) but has no effect on TBPB and VCP813 in
M1/3/4.
33,51,109,117,140 Interestingly, mutation of N6×58 does not
have a significant effect on the tested ligands in all muscarinic
receptors, even on LY2033298, although it forms an H-bond
with the cocrystallized LY2119620.33,141,142 The N4197×31K
and T4237×35H mutants decrease binding of gallamine and
W84 in M2 because of the introduced charge repulsion, but
mutation to other amino acids does not have a significant
effect.138,143 Mutation of W7×34 equivocally abolishes or
decreases binding of all tested allosteric ligands in M1/4 in
consensus with this residue being an important aromatic
stacking or cation−π interaction partner for both first- and
second-generation allosteric ligands.33,51−53 Finally, mutation
of several residues that do not have a generic number assigned
also has significant effects on ligand binding. The Q181A
mutation in human M1 located after the conserved triad in
ECL2 increases binding of BQCA but has no significant effect
on other allosteric modulators.51,53,109,135 The Q427A
mutation in human M4 located in ECL3 increases binding of
LY2033298.33 Several mutations in ECL2 furthermore
decrease or abolish binding of orthosteric ligands. The
R171A, F182A, and L183A mutants in human M1 ECL2 as
well as the corresponding mutants R171A in rat M1, R213I/T,
F224A, L225A in rat M3, and L190A in human M4 decrease
binding of acetylcholine, carbachol, atropine, NMS, and QNB.
These results are consistent with the fact that the phenyl-
alanine and leucine residues are facing the orthosteric binding
site and the arginine is stabilizing the conformation of ECL2 by
forming a salt bridge with D3×26 and an H-bond with Q4×65,
residues that are conserved in muscarinic recep-
tors.33,53,109,113,117,131,135,140,144,145
4.4. Structure-Based Extrapolation of Muscarinic
Acetylcholine Receptor Mutation Effects. Mutation data
predictions within the muscarinic acetylcholine receptor family
were performed for human data for M1, M2, M3, and M4
receptors with available crystal structures. The original
muscarinic acetylcholine receptor data that could be used for
extrapolation contained 504 points for the M1 receptor, 191 for
M2, 193 for M3, and 174 for M4, which referred to 16%, 12%,
20%, and 45% mutational data map coverage, respectively. In
retrospective studies, on average, 20% of original data points
were predicted: 23% (116 data points) for M1, 28% (54) for
M2, 12% (24) for M3, and 24% (41) for M4 with accuracies of
0.20, 0.70, 0.88, and 0.71, respectively. In prospective studies,
748 points could be predicted for M1 (however, the low
accuracy in retrospective studies indicates a potentially lower
quality for prospective predictions for this receptor subtype),
154 for M2, 136 for M3, and 104 for M4. The heat maps
referring to the original data set used for extrapolation, and the
retrospective and prospective predictions are provided in the
Supporting Information.
5. ADRENERGIC RECEPTOR MUTATIONS
5.1. Structural Adrenergic Receptor−Ligand Inter-
actions. Adrenergic receptors are activated by the small
neurotransmitter adrenaline (epinephrine). In humans, there
are nine adrenergic receptor subtypes, of which (turkey) β1
and β2 adrenergic receptors have already been crystallized. The
antagonists and inverse agonists 7-methylcyanopindolol (PDB:
5A8E152), bucindolol (PDB: 4AMI153), carazolol (PDB:
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2YCW154), carvedilol (PDB: 4AMJ153), cyanopindolol (PDB:
2VT4,155 2YCX, 2YCY,154 4BVN,36 5F8U156), indolylpiper-
azine (PDB: 3ZPQ73), iodocyanopindolol (PDB: 2YCZ154),
and quinolylpiperazine (PDB: 3ZPR73) and the full and partial
agonists carmoterol (PDB: 2Y02157), dobutamine (PDB:
2Y00, 2Y01157), isoprenaline (PDB: 2Y03157), and salbutamol
(PDB: 2Y04157) bound turkey β1 adrenergic receptor crystal
structures, and the antagonists and inverse agonists alprenolol
(PDB: 3NYA158), an aminopropyloxybenzofurane (PDB:
3NY9158), carazolol (PDB: 2RH1,2 4GBR,159 5D5A,
5D5B,160 5D6L,161 5JQH,162 5X7D163), timolol (PDB:
3D4S164), and the full and partial agonists adrenaline (PDB:
Figure 11. Adrenergic receptor mutation data.129,174−177,179,182−213 Data is shown for the consensus binding pocket defined using structure-based
generic position numbers from GPCRdb.18 Wild-type residues for the orthologues involved in mutation studies, and the mutant residues are shown
(note that only the mutations which have a data point shown in the table were actually carried out, the table is organized for comparability among
orthologues). Ligands are grouped similarly as in Figure 12. When multiple data points were available for the specific mutant−ligand combination,
the geometric mean of the fold effect values was used. See Figure 5 for color coding. Mutant numbers for each ligand and ligand numbers for each
mutant are indicated in the right side and the bottom of the heat map, respectively. The average fold effect (geometric mean) for each mutant is
also shown at the bottom of the heat map. PDF and Excel versions of the heat map are provided in the Supporting Information.
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4LDO165), BI-167107 (PDB: 3P0G,166 3SN6,167 4LDE165), a
covalent agonist (PDB: 4QKX168), FAUC50 (PDB: 3PDS169),
hydroxybenzylisoproterenol (PDB: 4LDL165), and ICI-
118,551 (PDB: 3NY8158) bound human β2 adrenergic
receptor crystal structures show a conserved ligand binding
mode in the orthosteric pocket, covering residues in the amine
pocket (D3×32, V3×36, W6×48, F6×51, N7×38, Y7×42) and major
pocket (V3×33, T3×37, Y5×39, A5×40, S5×43, S5×44, S5×461, F6×52,
N6×55). The interaction patterns with different residues
targeted in the minor pocket and extracellular vestibule
(G2×60, L/H2×63, V/I2×64, W3×28, T3×29, D45×51, F45×52, D/
K7×31, F/Y7×34, V/I7×35, W7×39) of β1 by the cocrystallized
ligands dobutamine, carmoterol, bucindolol, and carvedilol and
of β2 by the cocrystallized ligands BI-167107 and hydrox-
ybenzylisoproterenol determine the ligand-dependent struc-
ture−affinity, −function, and −selectivity relationships of
dualsteric adrenergic receptor ligands. The adrenergic receptor
crystal binding site structures are very conserved even among
the two different subtypes and active/inactive states. The
average heavy atom RMSD for β1 and β2 receptor subtypes are
0.8 and 1.0 Å, respectively. The average backbone RMSD for
these subtypes are 0.5 and 0.7 Å, respectively. The average
backbone RMSD for all adrenergic receptors is 0.6 Å, with the
largest difference of 1.2 Å between the antagonist salbutamol-
bound β1 and the agonist hydroxybenzylisoproterenol-bound
β2 (Figures 3, 13, and 20). In this case, the extracellular tip of
TM5 is shifted about 1.5 Å outward and the tips of TM6 and
TM7 about 1.2 and 2.4 Å inward in the agonist-bound
structure relative to the antagonist-bound structure. Ligand
binding modes are also very well conserved in adrenergic
crystal structures, the orthosteric aromatic moieties, and the
key H-bonding ethanolamine moieties almost perfectly overlap
among structures. There is some variation in the aromatic
moieties used in the minor pocket, the shorter ones interact
with F/Y7×34 and W3×28, while the longer ones interact with
W7×39 and Y7×42. In the amine pocket, D3×32 and N7×38 form a
concerted H-bond interaction network with ethanolamine
moieties present in 52 of the 125 β-adrenergic ligands
investigated in mutation studies. Ligands lacking the hydroxyl
group such as the piperazine moieties of the small, fragment-
like indolylpiperazine and quinolylpiperazine ligands do not
form concerted H-bonds with the β-adrenergic receptor
specific residue N7×38 but target the same amine pocket and
form an ionic interaction with D3×32, providing a structural
template for piperazine containing ligands in adrenergic
receptors consistent with the essential role of the cationic
properties of the amine group of ethanolamine ligands in
mutational studies and other β-adrenoreceptor ligands (section
5.3.1). The catechol, quinolinone, benzoxazinone, indole,
carbazole, and other aromatic scaffolds of the cocrystallized
ligands form hydrophobic interactions with V3×33, F45×52, Y5×39,
A5×40, F6×51, F6×52 and form H-bond interactions with S5×43 and
often with S5×46 and N6×55 in the major pocket between TM3−
6. The endogenous ligand adrenaline (in the structure 4LDO,
the only aminergic GPCR crystal structure with an endogenous
ligand) forms all of the aforementioned H-bonds in the amine
and the major pockets. Mutation studies demonstrate the
important role of these hydrophobic and polar residues
(section 5.3.2), and SAR studies show the preference of
adrenergic receptors for ligands with aromatic moieties with at
least one polar H-bond interaction functionality, mimicking
the catechol group of adrenaline. In the minor pocket and
extracellular vestibule, the arylalkyl appendages of the
cocrystallized ligands carmoterol, carvedilol, BI-167107, and
FAUC50 form hydrophobic/aromatic interactions with
W23×50, W3×28, F/Y7×34, V/I7×35, and W7×39 and polar groups
of dobutamine, bucindolol, and hydroxybenzylisoproterenol
form H-bonds with residues D45×51, W7×39, and the backbone
of C45×50 that are also available for polar interactions with
minor pocket binding appendages of ligands such as CGP-
20712. Furthermore, S2×60 and K/Q7×35 in α-adrenoreceptors,
N2×63 in α2-adrenoreceptors, and the variable Q/E/K/D
45×51
and E/D/R/H/K7×31 might provide polar anchor points for
dualsteric adrenergic ligands. The β2 adrenergic receptor is
unique among aminergic GPCRs in that it is the only one
crystallized in a ternary complex with an orthosteric antagonist
(carazolol) and an intracellular allosteric synthetic peptide
antagonist (Cmpd-15) (PDB: 5X7D163). The data set contains
91 mutation data points associated with residue positions
lining the intracellular binding pocket of Cmpd-15, 5-
HT1A/2A/2C/7, M1/2/3/5, α1B/2A, and β2. It should be noted
however that all these studies used orthosteric radioligands,
and therefore the observed effects possibly originate from
differential G protein binding.
5.2. Chemical Space of Adrenergic Receptor Ligands
in Crystal Structures and Mutation Studies. Nine of the
cocrystallized β-adrenergic receptor ligands, the endogenous
agonist epinephrine (212, Figure 13), the partial/full agonists
carmoterol (12 mutation data points), dobutamine (4),
isoproterenol (111), salbutamol (3), and the antagonists/
inverse agonists iodocyanopindolol (84, Figure 13), alprenolol
(12), ICI-118,551 (11), and timolol (7) have been extensively
investigated in mutation studies of seven receptors, covering
201 mutations of 99 residues in total (Figure 11). Twenty-
three of these residues line the binding sites of these ligands in
β1 and β2 adrenergic receptor crystal structures (Figure 3). The
cocrystallized BI-167107, bucindolol, carazolol, carvedilol, 7-
methylcyanopindolol, cyanopindolol, FAUC50, hydroxylben-
Figure 12. Adrenergic receptor ligands used in mutation studies.129,174−177,179,182−213 Cocrystallized ligands in β1 and β2 structures shown in red.
Chemically similar ligands to any of the cocrystallized ligands in adrenergic receptor crystal structures indicated with orange background,
chemically similar ligands to any cocrystallized ligand in aminergic receptor crystal structures indicated with a cyan background. Receptors with
available mutation data for the specific ligand are indicated along with the number of data points in parentheses. A PDF version of the figure is
provided in the Supporting Information.
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zylisoprenaline, indolylpiperazine, and quinolylpiperazine
ligands in complex with β1 adrenergic and β2 adrenergic
crystal structures have not yet been investigated in mutation
studies but share chemical and binding mode similarity170 with
the crystallized ligands for which mutation data are available.
Thirty ligands that share the 2-amino-1-phenylethan-1-ol
substructure with cocrystallized (agonist) ligands (including
norepinephrine, phenylephrine) and 22 ligands that share the
1-amino-3-phenoxypropan-2-ol substructure with crystallized
inverse agonists/antagonists (including CGP-1277, CGP-
20712, propranolol) cover 506 (38%) and 290 (22%)
ligand−mutant combinations, respectively. Thirty-three
(26%) of the ligands investigated in mutation studies
(excluding cocrystallized ones) are chemically similar to any
of the cocrystallized β1 and β2 adrenergic receptor ligands
(including nonethanolamines RS-17053 and indoramin) and
cover 318 (24%) ligand mutant combinations (Figure 12).
Compounds that do not share chemical similarity with any
aminergic cocrystallized ligand cover 541 different mutant−
ligand combinations, including 2-phenoxyethan-1-amines (e.g.,
WB-4101, tamsulosin), imidazolines (e.g., phentolamine,
oxymetazoline, cirazoline, UK-14304, clonidine), phenylpiper-
azines (including 5-methylurapidil), aminoquinazoline piper-
azines (prazosin, terazosin), niguldipine analogues, and tetra/
pentacyclic amines (yohimbine). However, 35 (28%) com-
pounds are pharmacophorically similar to any of the
cocrystallized ligands. In addition, nonselective aminergic
receptor ligands ketanserin, spiperone, and chlorpromazine
have been investigated in adrenergic, serotonin, and dopamine
receptor mutation studies, and several other ligands including
alprenolol, propranolol, labetalol, and pindolol were studied in
adrenergic and serotonin receptors and noradrenaline and
dopamine were studied in adrenergic and dopamine receptors,
providing insights into the receptor specific determinants of
binding of these ligands by different aminergic GPCRs.
5.3. Structural Determinants of Adrenergic Recep-
tor−Ligand Interactions. 5.3.1. Amine and Major Pocket
Mutations in Adrenergic Receptors. Mutation of conserved
D3×32 to nonacidic residues has been shown to diminish
binding of epinephrine, ketanserin, tamsulosin, and niguldipine
at the α1B adrenergic receptor (D125
3×32A and D1253×32K)
and adrenaline, noradrenaline, isoprenaline, iodocyanopindo-
lol, and propranolol at the β2 adrenergic receptor (D113
3×32E/
N/S).171−173 Y7×42 stabilizes the conformation of D3×32
through a hydrogen bond in adrenergic receptors, and not
surprisingly also the Y3387×42A mutation in hamster α1B
abolishes binding of the endogenous ligands and the inverse
agonist prazosin.174,175 The β2 adrenergic receptor affinities of
the β adrenergic selective ligands alprenolol, epinephrine,
isoproterenol, and propranolol are decreased for the
N3127×38Q and N3127×38T mutants and pindolol affinity is
decreased by the N3127×38T mutant (but not by the
N3127×38Q mutant),176 consistent with the important role of
this β adrenergic specific residue in binding the ethanolamine
moieties of both agonists and antagonists in β1 adrenergic and
β2 adrenergic receptor crystal structures. The same N312
7×38Q
and N3127×38T mutants increase β2 affinity for the α2A
antagonists yohimbine and para-aminoclodine,176 confirming
N7×38 as an important determinant of β adrenergic receptor
selectivity versus F7×38 in α adrenergic receptors. F7×34A/L or
F7×38A mutations significantly decrease affinity for the α1
antagonists (BMY7378, 5-methylurapidil, niguldipine, prazo-
sin, and WB4101) and small imidazoline partial agonists
(cirazoline, clonidine, and oxymetazoline) but do not affect the
affinity for nonselective phenethylamine agonists (epinephrine,
methoxamine, phenylephrine) or the more bulky phentol-
amine.177 The F7×34L mutant increases the affinity for the β-
adrenergic receptor antagonist alprenolol, but not of
propranolol, consistent with the interaction of the ethylene
group of alprenolol with the homologous Y3087×34 residue in
the β2 adrenergic receptor crystal structure. F
7×34A/L or F7×38A
mutants also decrease α1 binding of the small imidazoline-
containing partial agonist cirazoline, clonidine, and oxymetazo-
line but do not have an effect on binding of the bulkier
imidazoline antagonist phentolamine, which may be able to
compensate the loss of interactions with F7×34/F7×38 by
accommodating two instead of one phenyl ring in the
hydrophobic major pocket between W6×48, F6×51, F6×52, and
F6×55. This binding mode hypothesis is consistent with the
large decrease of phentolamine and 5-methylurapidil binding
affinities for the F3106×51A/L and F3116×52A/L mutants in
α1B.
178 The affinity of prazosin is only affected by the
F3106×51A and F3116×52A/L mutations and not by the
F3106×51L mutation, whereas the binding affinity of HEAT
(Figure 13) is only decreased by the F3106×51C and
F3116×52A/C mutations.178 This comparative analysis indicates
Figure 13. Adrenergic receptor ligand binding modes and associated mutation data. (A) β1 (PDB: 2YCZ
154) with cocrystallized
iodocyanopindolol, mutation effects mapped on structure for β1/2-iodocyanopindolol. (B) β2 (PDB: 4LDO
165) with cocrystallized adrenaline,
mutation effects mapped on structure for β2-adrenaline. (C) α1B homology model from GPCRdb with docked HEAT, mutation effects mapped on
structure for α1B-HEAT. See Figure 5 for color coding. Mutation effects for alanine mutants were used where available.
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that the roles of hydrophobic/aromatic interactions with
F3106×51 and F3116×52 are ligand-dependent and suggest
different binding modes of the aromatic moieties of 5-
methylurapidil, phentolamine, prazosin, and HEAT in the
major pocket of the α1A adrenergic receptor. Interestingly,
although F6×44 is located deep in the binding pocket, mutation
of this residue to the smaller residues glycine, alanine, or
leucine increases affinity of adrenaline178,179 by affecting the
activation mechanism of GPCRs. Mutation of F3036×44
reduces the hydrophobic hindering mechanism and thereby
also increases the constitutive activity of the receptor.180,181
S5×43A/C/V or S5×461A mutants of α1B, α2A, and β2 receptors
affect binding of phenethylamine agonists with a meta-hydroxyl
moiety (carmoterol, epinephrine, isoprenaline, meta-hydroxyl
isoprenaline, norepinephrine, norphenephrine, phenylephrine)
and phenoxyethylamine antagonists with polar substituents
connected to the phenoxy group (CGP-12177, pindo-
lol).179,182−187 In contrast, α1B, α2A, and β2 receptors affinities
for phenethylamine agonists that only contain a para-
substituted hydroxyl group (para-hydroxyl isoprenaline, octop-
amine, salbutamol) or ligands that do not contain a polar
substituent at 5−7 Å from the amine group (alprenolol,
clonidine, halostachine, phentolamine, propranolol, synephr-
ine) are not affected by these mutations.182,183,188,189 The
ligand-dependent effects of S5×43 and S5×461 are consistent with
the role of these residues as H-bond interaction partners of
polar groups in isoproterenol, BI-167107, carmoterol,
epinephrine, and pindolol in β1 and β2 adrenergic receptor
crystal structures. S5×461 mutants furthermore decrease the
binding affinities of α2A for ligands that contain polar atoms at
5−7 Å from the imidazoline nitrogen (atipamezole, idazoxan,
oxymetazoline, RX-811059, RX-821002, UK-14304),189 pro-
viding useful constraints to construct structural imidazoline
bound α adrenergic receptor models. The V5×40A mutant
decreases α1A affinity for piperidine oxazole compounds 1−6,
but not of compounds 7−11, suggesting that the trifluoro-ethyl
substituents of compounds 1−6 interact with this residue. The
mutations S5×44A in α1B and β2, S
5×44C in mouse α2A and β2
and C5×44S in human/pig α2A have a highly receptor subtype
and also ligand-dependent effects. For example, the S5×44A
mutation has no effect on any ligand binding in α1B
182,188 but
negatively affects most ligands in β2, except for phenethyl-
amines with only a para-hydroxyl substituent, suggesting a
somewhat altered binding mode for these ligands.185−187,190
The S2015×44C mutant in mouse α2A has no effect,
191 but the
same mutant in β2 abolishes isoprenaline binding.
185,187,190
The reverse C5×44S in human/pig α2A reduces binding of all
adrenaline analogues but generally has no effect on non-
phenethylamine ligands,191−193 implying that this residue
might be involved in the polar interaction network around
TM3, 5, 6 although it is not seen to form H-bonds with
cocrystallized ligands. The same is true for Y5×39 as the Y5×39A
mutation abolishes binding of the endogenous ligands, while it
does not affect that of prazosin.188 This residue is seen to form
an H-bond with S5×43 in multiple crystal structures, thus it is
plausible that this extended network of polar contacts is
required for adrenergic receptor function. The N6×55L mutant
in the β2 receptor, which is also seen to form an H-bond with
acceptor moieties of cocrystallized ligands, abolishes binding of
(nor)adrenaline and isoprenaline but not of several other
catechol compounds, therefore it is possibly an important
recognition point for the less tight binding ligands but not as
important for more optimized ligands.194 This is underlined by
the fact that in α receptors this position features hydrophobic
residues and mutation of these does not affect binding of a
range of ligands. The T1303×37A mutant of the α1B adrenergic
receptor has decreased affinity for the antagonists ketanserin,
niguldipine, prazosin, and tamsulosin but unaffected binding
affinity for the agonists epinephrine and norepinephrine.188
The C1173×36V mutant of the α2A adrenergic receptor is not
compatible with high affinity binding of the antagonists
phenoxybenzamine and phentolamine but does not affect
binding of the antagonist RS-79948,195 suggesting that
phenoxybenzamine and phentolamine bind deeper in the
major pocket than RS-79948.
5.3.2. Minor Pocket and Extracellular Vestibule Mutations
in Adrenergic Receptors. Relatively little mutation data is
available for the minor and extracellular vestibule in adrenergic
receptors. The F862×63M mutant in the α1A adrenergic receptor
decreases binding of piperidine oxazole compounds 2−5 and
12, suggesting that the phenethyl appendage of this series of
ligands interacts with F862×63.196,197 This mutation also
reduces affinity of dihydropyridines 1−3, indicating that the
bulky dihydropyridine moiety contacts TM2 in the extrac-
ellular vestibule. The reverse M1562×63F mutant in α1D
accordingly increases the affinity of these ligands. Neither the
I1182×63A nor the V1192×64A mutants affect binding of the
agonist RO363 to β1.
177 This observation suggests that the
appendage of this ligand rather contacts F3257×34 in the same
way as carmoterol in the 2Y02 crystal structure.157 Mutations
at positions 45×51 and 45×52 in ECL2 have only been
reported for the α1B receptor. This subtype has an unusual
G45×51 residue; however, mutation of this to larger polar
residues does not affect ligand binding, which is consistent
with the conformation pointing away from the ligand binding
site in β1/2 crystal structures.
198 The V45×52I mutation has
minor effects on the bulky hydrophobic antagonists HEAT and
WB-4101 but not on other tested ligands, including adrenaline,
phentolamine, methoxamine, and oxymetazoline.198 Other
mutations in ECL2 include the cysteine bridge between
C184 and C190 in the β2 receptor. Disruption of this link is
detrimental to binding of several tested ligands by modifying
the structure/dynamics of ECL2. Mutations at positions 6×59
and 7×31 on the tops of TM6 and 7 have no effect on the
tested ligands, but it is unlikely that even bitopic ligands would
extend toward these residues.177,188 Finally, the K3317×35A/E/
Q mutations in α1B increase binding of (nor)adrenaline,
possibly by removing the charge−charge repulsion with these
small ligands but have no effect on prazosin and HEAT.175
Mutation of the analogous hydrophobic residues in the β
receptors to alanine reduces binding of ligands with arylalkyl
appendages carmoterol and salmeterol but not RO363 and
ligands without a large appendage.177,199,200
5.4. Structure-Based Extrapolation of Adrenergic
Receptor Mutation Effects. Mutation data predictions
within the adrenergic receptor family were performed for
human data for only the β2 receptor with available crystal
structures. Due to the limited number of data points and low
interaction fingerprint similarity of the ligands, no predictions
could be made for the β1 receptor despite having many crystal
structures at hand. The original adrenergic receptor data that
could be used for extrapolation contained 299 data points
(11% coverage); retrospective studies predicted 23% of points
(70), and 748 points were a result of the prospective analysis.
Accuracy of the retrospective predictions was 0.59. The heat
maps referring to the original data set used for extrapolation,
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and the retrospective and prospective predictions are provided
in the Supporting Information.
6. DOPAMINE RECEPTOR MUTATIONS
6.1. Structural Dopamine Receptor−Ligand Interac-
tions. Dopamine receptors are activated by the small
neurotransmitter dopamine. In humans, there are five
dopamine receptor subtypes of which the D2, D3, and D4
receptors have been crystallized.38 The antagonist eticlopride
bound D3 (PDB: 3PBL
38) and antagonist nemonapride bound
D4 (PDB: 5WIU, 5WIV
39) crystal structures show a conserved
binding mode of the pyrrolidinylmethylbenzamide scaffold in
the orthosteric pocket, covering residues in the amine pocket
(D3×32, C3×36, W6×48, F6×51, T7×38, Y7×42) and major pocket
(V3×33, T3×37, F/Y5×39, V5×40, S5×43, S5×44, S5×461, F6×52, H6×55,
I/V6×56). Only a few residues are in contact with eticlopride in
the minor pocket and extracellular vestibule (V2×56, F/V2×60,
L/S2×63, F/L3×28, M/V3×29, I/L45×52, V/Y7×34). The benzyl
moiety of nemonapride further opens up a subpocket between
TM2 and TM3 between L2×59 and L3×28 in D4.
39 These
residues are W2×59 and F/W3×28 in other dopamine receptors,
respectively, and their aromatic rings are oriented away from
each other, W2×59 toward the membrane and F/W3×28 toward
the binding pocket. Therefore, this subpocket possibly only
exists in D4. A plethora of dualsteric ligands are available for
dopamine receptors, such as the cocrystallized antagonist
risperidone in D2 (PDB: 6CM4
37), which extends toward the
extracellular vestibule. The tetrahydropyridopyrimidinone
appendage of risperidone forms a water-mediated H-bond
with H6×55, aromatic interactions with W23×50, F3×28, F6×51, and
Y7×34, and contacts with V2×60, L2×63, and T7×38. Other residues
available for polar interactions in the extracellular vestibule
include E2×64, D/S7×35, and T7×38, which determine the ligand-
dependent structure−affinity, −function, and −selectivity
relationships of dopamine receptor ligands. There are only a
few dopamine receptor crystal structures, but substantial
variations could be seen among the different subtypes in the
extracellular tips of TM5−7 helices and all ECL conforma-
tions. The average heavy atom RMSD for D3, and D4 receptor
subtypes is 0.4 Å. The average backbone RMSD for these
Figure 14. Dopamine receptor mutation data.214−217,219−241 Data is shown for the consensus binding pocket defined using structure-based generic
position numbers from GPCRdb.18 Wild-type residues for the orthologues involved in mutation studies and the mutant residue are shown (note
that only the mutations which have a data point shown in the table were actually carried out, the table is organized for comparability among
orthologues). Ligands are grouped similarly as in Figure 15. When multiple data points were available for the specific mutant−ligand combination,
the geometric mean of the fold effect values was used. See Figure 5 for color coding. Mutant numbers for each ligand and ligand numbers for each
mutant are indicated in the right side and the bottom of the heat map, respectively. The average fold effect (geometric mean) for each mutant is
also shown at the bottom of the heat map. PDF and Excel versions of the heat map are provided in the Supporting Information.
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subtypes are 0.3 and 0.1 Å, respectively. The average backbone
RMSD for all dopamine receptors is 1.33 Å, with the largest
difference of 2.3 Å between the risperidone-bound D2 and the
nemonapride-bound D4 (Figures 3, 16, 20). In this case, the
extracellular tips of helices TM4−7 are shifted about 2−2.5 Å
relative to each other. D3 and D4 crystal structures show a
similar binding mode of the benzamide ligands, however, as
mentioned earlier, in D4 an extra subpocket is opened between
TM2 and TM3, and the extracellular tips of TM6 and TM7 are
also shifted relative to each other by 2 and 1.2 Å, respectively.
On the other hand, risperidone in D2 opens a deep subpocket
in the hydrophobic core of the receptor, reaching I3×40 as seen
also in the methiothepin and ritanserin-bound serotonin crystal
structures. Furthermore, the extracellular tip of TM5 is shifted
2.8 Å inward and the tip of TM6 4 Å outward in D2 relative to
the other dopamine receptors. In the amine pocket, D3×32
forms an ionic interaction with the amine group of basic
ligands such as pyrrolidinylmethylbenzamide, aminotetralin,
aryl-piperidine, and aryl-piperazine compounds, while residue
Y7×42 stabilizes the conformation of D3×32 and residues W6×48
and F6×51 form cation−π interaction, consistent with mutation
studies (section 6.3.1) and SAR studies, showing the essential
role of the cationic properties of the amine group of most
dopamine receptor ligands. The substituted benzamide moiety
of the cocrystallized ligands eticlopride and nemonapride make
hydrophobic interactions with V3×33, C3×36, I45×52, F6×51, F6×52,
and H6×55 in D2/3. Risperidone furthermore contacts I
3×40,
F5×47, and F6×44 in a deeper orthosteric binding pocket in D2.
Nemonapride forms an H-bond with S1925×43 and halogen
bond with S1935×44 in D3. The endogenous ligand, dopamine,
potentially forms H-bond interactions with T3×37, S5×43, S5×44,
and/or S5×461 in the major pocket between TM3−6 in
dopamine receptors. Mutation studies demonstrate the
important role of these hydrophobic and polar residues
(section 6.3.2), and SAR studies demonstrate the preference
of dopamine receptors for ligands with multiply substituted
aromatic moieties binding this region. Ortho- and meta-
substitution with hydrophobic substituents are beneficial on
benzamide and aryl-piperazine ligands, such as in the privileged
2,3-dichlorophenylpiperazine scaffold and various phenol
bioisosteres, are also employed mimicking the catecholamine
group of the endogenous ligand. Interestingly, the mutation of
S5×43, S5×44, S5×461, and H/N6×55 show highly ligand-dependent
effects in D1−4. In the D3 crystal structure, an H-bond network
is formed by Y3657×34, H3496×55, and the backbone of
I18345×52, creating a lid over the major pocket, but there is a
tunnel toward the minor pocket from the amine pocket. Only a
few data points are available for the minor pocket and
extracellular vestibule in combination with dualsteric ligands
(e.g., for polar residues E2×64, T7×38, and hydrophobic residues
V2×60, L2×63, and Y/F7×34). However, no data is yet available for
D/S7×35 that potentially also forms H-bond interactions with
ketone or heterocyclic amide groups of dualsteric ligands such
as buspirone, aripiprazole, domperidone, haloperidol, and
spiperone.
6.2. Chemical Space of Dopamine Receptor Ligands
in Crystal Structures and Mutation Studies. The
cocrystallized dopamine receptor ligands eticlopride (30
mutants), nemonapride (52 mutants), and risperidone (22
mutants) as well as close analogues raclopride (35 mutants,
Figure 16), sulpiride (37 mutants), and the endogenous
dopamine (64 mutants, Figure 16) have been extensively
investigated in mutation studies of the dopamine D1, D2, D3,
and D4 receptors covering 27 different residues in total (Figure
14). Seventeen of these residues line the binding site in the
dopamine receptor crystal structures (Figure 3). Sixteen (12%)
of the ligands investigated in mutation studies are chemically
similar, and 12 (9%) are pharmacophorically similar to the
cocrystallized ligands (Figure 15). All benzamide ligands
(including analogues with noncyclic or a tropane basic moiety)
have been investigated at 182 (20%) ligand−mutant
combinations in total. Phenethylamine analogues have been
investigated at 235 (28%) ligand−mutant combinations in
total. Aryl-piperidine and aryl-piperazine ligands have been
Figure 15. Dopamine receptor ligands used in mutation studies.214−217,219−241 Cocrystallized ligands in the D2, D3, and D4 structures shown in red.
Chemically similar ligands to the cocrystallized ligands in dopamine receptor crystal structures indicated with orange background, chemically
similar ligands to any cocrystallized ligand in aminergic receptor crystal structures indicated with a cyan background. Receptors with available
mutation data for the specific ligand are indicated along with the number of data points in parentheses. A PDF version of the figure is provided in
the Supporting Information.
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investigated at 169 (18%) ligand−mutant combinations in
total. Most of these compounds do not share 2D chemical or
3D shape/pharmacophore-based similarity with the cocrystal-
lized dopamine receptor ligands but represent combined ligand
and receptor SAR data sets that provide detailed information
on the structural determinants of dopamine receptor binding.
Moreover, 10 ligands are chemically similar to cocrystallized
ligands in serotonin and adrenergic receptor complexes, such
as ergolines terguride, lisuride and bromocriptine, endogenous
dopamine and noradrenaline, and aryl-piperazines with
heterocyclic substitutions at the basic amine (e.g., CPPMA).
Several nonselective aminergic receptor ligands, including
clozapine, spiperone, chlorpromazine, lisuride, and haloperidol,
have been investigated altogether at 98 different dopamine
receptor mutants, as well as mutants at other receptor
subfamilies (e.g., clozapine was used in serotonin, muscarinic,
dopamine, and histamine receptor mutation studies), providing
insights into the receptor specific determinants of binding of
these ligands by different aminergic GPCRs.
6.3. Structural Determinants of Dopamine Receptor−
Ligand Interactions. 6.3.1. Amine and Major Pocket
Mutations in Dopamine Receptors. Mutation of the
conserved D3×32 to nonacidic residue alanine has only been
tested for nemonapride and risperidone, where it abolished
functional activity in both cases.37 Mutation to glutamic acid
(D1103×32E) has been shown to diminish binding for 9 of 12
ligands in the dopamine D3 receptor, including the endogenous
dopamine, 7-OH-DPAT, cyclohexene-amine agonists, and the
dualsteric FAUC329, FAUC335, and spiperone (Figure 16)
ligands, indicating that not only the ionic interaction with the
anionic carboxylate group of D3×32 is required for ligand
binding but also the size of the residue is of importance.214,215
The Y7×42F mutant in D2/3 lacking a stabilizing H-bond
interaction with D3×32 has no pronounced effect on the binding
of orthosteric ligands such as the antagonists eticlopride,
sulpiride, DO-710, and metoclopramide; however, it decreases
binding of the antagonists nemonapride, flupentixol, and PF-
4363467 with larger appendages on the basic amine and
dualsteric ligands haloperidol, domperidone, spiperone, and
GSK598809, suggesting that the H-bond between Y7×42 and
D3×32 is important in shaping the secondary binding pocket in
dopamine receptors.216−218 Interestingly, D1 and D5 are among
the few aminergic receptors (along with histamine H3 and H4)
with a tryptophan at the 7×42 position. Mutation to the more
abundant tyrosine in D1 (W
7×42Y) does not affect binding of
three ligands including that of the endogenous dopamine.219
There is also a difference at position 3×36 between D1-like and
D2-like receptors. There is no mutation data available for this
position in D1 and D5, where the residue is a serine, but there
is data available for D2 and D3, where it is a cysteine. The
C1183×36A/M/S mutations in D2 do not affect binding of
dopamine and the orthosteric antagonists nemonapride and
sulpiride, while the C1143×36L/M/S mutation is detrimental to
binding of 13 different ligands in the D3 receptor, suggesting a
differential role of this residue even in the two similar
receptors.37,218,220−223 Another difference in the amine pocket
between the two families is V/T7×38. The V3177×38T mutant in
D1 and the T412
7×38A/V mutants in D2 do not have a
significant effect on binding of 11 ligands but decrease binding
of nemonapride and risperidone. In D3, the T369
7×38V mutant
again does not have an effect on binding of nine ligands but
increases binding of the agonists dopamine and 7-OH-DPAT
and the antagonist GR218231, possibly by enhancing hydro-
phobic complementarity with propyl groups of the two latter
ligands. Finally, the T7×38A mutant in D4 has a ligand-
dependent effect, decreasing binding of five investigated
ligands (the hydroxyl group of butaclamol, the most affected
ligand, possibly forms an H-bond with this residue) and
increasing binding of six investigated ligands and does not have
an effect on 12 other ligands. Even very similar ligands are
differentially affected by this mutation; therefore, it is
hypothesized that this mutation affects the dynamics of the
binding pocket or the whole receptor rather than introducing
local changes in the ligand environment. Mutations T1193×37A
and I1223×40A located in the deep pocket induced by
risperidone as expected affect risperidone binding but not
that of nemonapride, which does not penetrate so deep in the
binding site.37 Disruption of the aromatic cage in the major
pocket generally results in severe effects on ligand binding. The
F3456×51A/W mutation is equivocally detrimental to binding
of 14 investigated ligands except spiperone in D3.
37,214,224 The
F3906×52A/W mutant is similarly detrimental for seven
different ligands in D2.
37,224,225 Mutations of the hydrophobic
residue at position 5×40 are only studied for 1−1 ligand in D1
Figure 16. Dopamine receptor ligand binding modes and associated mutation data. (A) D3 (PDB: 3PBL
38) with docked raclopride, analogue of
cocrystallized eticlopride, mutation effects mapped on structure for D2/3-raclopride. (B) D3 (PDB: 3PBL) with docked dopamine, mutation effects
mapped on structure for D2/3-dopamine. (C) D3 (PDB: 3PBL) with docked spiperone, mutation effects mapped on structure for D2/3-spiperone.
See Figure 5 for color coding. Mutation effects for alanine mutants were used where available.
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and D2, where it decreases binding, while in D3 it showed less
pronounced effects, possibly depending on how deep the
specific ligands are able to penetrate in the binding site.217,218
Mutation of hydrophobic residues on the other face of the
cocrystallized ligand eticlopride I/V3×33, I/L/S45×52, and F/
Y5×39 do not have a pronounced effect on the binding of
ligands,217,222 which is consistent with the location of this
residue further away (∼6Å from eticlopride) in the dopamine
D3 crystal structure than in other aminergic receptors. Polar
residues in the major binding pocket S5×43, S5×44, and S5×461
have been mutated to alanine and evaluated for almost 70
ligands in D1−4. These have been the most studied mutations
in dopamine receptors, unsurprisingly, as these form crucial H-
bond interactions with the catechol moiety of the endogenous
ligand dopamine. The S5×43A and S5×44A mutants negatively
affect binding of phenethylamine agonists with a meta-hydroxyl
moiety (e.g., agonists dopamine, noradrenaline, dipropyl-6,7-
ADTN, 7-OH-DPAT) but increase binding of halogen
substituted eticlopride analogues (e.g., antagonists FLA-797,
remoxipride, metoclopramide), suggesting that these serines
interact with the meta position of the aromatic ring
substitution.226−235 This also suggests that eticlopride
analogues with a methoxy instead of a hydroxyl group in the
ortho position might have a flipped aromatic ring relative to
the cocrystallized eticlopride. On the other hand, the S5×461A
mutant affinities for phenethylamine agonists that contain a
para-substituted hydroxyl group (dopamine, noradrenaline,
dipropyl-5,6-ADTN) or other ligands containing a polar
substituent at the corresponding position (BRL 25594,
raclopride, sulpiride, domperidone) are affected by this
mutation.226−231,233,235 Finally, mutations in the polar lid
formed above the major pocket by Y7×34, H6×55, and I45×52 also
have ligand-dependent effects in dopamine receptors. The
H6×55L mutation decreases binding of several eticlopride
analogues but increases binding of benzamide-1, metoclopra-
mide, and clebopride containing a para-NH2 group, implying
that these ligands move toward the extracellular space to
accommodate the additional polar group.236,237 The H6×55A/F
furthermore increases binding of, e.g., the FAUC series of
dualsteric ligands, possibly by creating space above the major
pocket by reducing the size of the lid or by disrupting the H-
bond network.238 The Y7×34F/L/V mutants increase binding of
spiperone and clozapine but decrease binding of risperidone,
PF-4363467, and N-methylspiperone.217,218,222
6.3.2. Minor Pocket and Extracellular Vestibule Mutations
in Dopamine Receptors. Relatively few mutation data points
are available for the minor pocket and extracellular vestibule in
dopamine receptors. The space between TM2 and TM7 is
somewhat larger than in other aminergic receptors, and this
pocket is hypothesized to be accessible by most dualsteric
ligands, as seen in the D2-risperidone complex (6CM4).
Mutation of K812×60 in D1 has no effect on binding of small
orthosteric ligands.219 The V912×60F mutation in D2 increases
binding of CPPMA, possibly by the additional aromatic
stacking interaction,222 and the reverse F912×60V mutant in D4
decreases binding of the closely related L750,667 by the loss of
this stacking interaction.239 In contrast, the V862×60F mutation
in D3 (contacting the pyrrolidine ring of cocrystallized
eticlopride) decreases binding of the dualsteric FAUC series
of molecules, possibly by decreasing the size of the minor
pocket, whereas these ligands are larger than CPPMA in D2
and D4.
215 Hydrophobic residues at positions 3×28 and 3×29
also contact the pyrrolidine ring of eticlopride but have only
been mutated in other dopamine receptor subtypes. As
mentioned in section 6.1, the benzyl moiety of nemonapride
opens up a subpocket between TM2 and TM3 between
L902×59 and L1113×28 in D4,
39 which probably does not exist in
other dopamine receptor subtypes, as both of these residues
are large aromatic ones. Indeed, the L902×59W mutation in D4
increases binding of the antagonists raclopride, OPC-4392,
aripiprazole and N-methylspiperone, possibly by forcing
L1113×28 to face the binding site as found in the D4 crystal
structure and increasing complementarity with ligands not
containing overlapping moieties with the benzyl group of
nemonapride. The F1103×28L mutation increases binding of
the antagonist CPPMA and the V1113×29M mutation decreases
binding of N-methylspiperone, possibly also by modulating the
size of the minor pocket, but they do not have a significant
effect on several other ligands in D2.
222 Conversely, in D4, the
M1123×29V mutation increases the size of the minor pocket
and thus increases binding of, e.g., raclopride, nafadotride, and
A-69024.239 Mutation of L2×63 and E2×64 has no significant
effect on orthosteric ligand binding, e.g., that of eticlopride and
PF-4363467, but has a pronounced, but varying (decreasing
and increasing) effect on binding affinity for dualsteric
risperidone, aripiprazole, N-methylspiperone, haloperidol, and
GSK598809 in D2/3/4.
37,218 The unique conformation seen for
the conserved W10023×50 in ECL1 in the dopamine D2
receptor justifies its large disruptive effect on dualsteric ligand
binding in D2.
37 However, mutations in other subtypes have
not been performed, and thus its effect cannot be compared to
cases when it is not contacting ligands. Only one data point is
available for the S7×35D mutant in D3 that mimics the D1-like
receptors, but it does not have any effect on spiperone binding.
Finally, the mutation Y361×39L/F is not involved in our
binding site selection as this residue does not contact any
cocrystallized ligands in aminergic receptor crystal structures,
but it seems to be accessible in the minor pocket in the D3
crystal structure. This mutation indeed does not have any
effect on the investigated orthosteric ligands (agonists
dopamine, 7-OH-DPAT, and antagonists GR218231, chlor-
promazine, and raclopride) but decreases binding of dualsteric
haloperidol and GSK598809.218,237
6.4. Structure-Based Extrapolation of Dopamine
Receptor Mutation Effects. Mutation data predictions
within the dopamine receptor family were performed for
human data for the D3 receptor with an available crystal
structure. Retrospective predictions for dopamine receptor D3
were performed with 0.78 accuracy. The initial 197 points used
for extrapolation (14% of coverage) were predicted for 39%
(77 points) in retrospective studies, and prospective analysis
resulted in a heat map with 193 points (14% coverage). The
heat maps referring to the original data set used for
extrapolation, and the retrospective and prospective predic-
tions are provided in the Supporting Information.
7. HISTAMINE RECEPTOR MUTATIONS
7.1. Structural Histamine Receptor−Ligand Interac-
tions. Histamine receptors are activated by the small
neurotransmitter histamine. In humans, there are four
histamine receptor subtypes of which H1 has been crystal-
lized.40 The doxepin bound H1 (PDB: 3RZE
40) crystal
structure shows a binding mode of a tricyclic amine scaffold
in the orthosteric pocket, covering residues in the amine
pocket (D3×32, S3×36, W6×48, Y6×51, I7×38, Y7×42) and the major
pocket of histamine receptors (Y3×33, T3×37, I3×40, W4×57, T5×43,
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.8b00836
J. Med. Chem. 2019, 62, 3784−3839
3815
Figure 17. continued
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.8b00836
J. Med. Chem. 2019, 62, 3784−3839
3816
A5×44, N5×461, F5×47, F6×44, F6×52, F6×55). The interaction
patterns with different residues targeted in the minor pocket
and extracellular vestibule (Y2×63, W3×28, L3×29, E45×51, T45×52,
I6×58, A6×59, E7×31, H7×34, M7×35) by dualsteric ligands may
furthermore modulate the ligand-dependent structure−affinity,
−function, and −selectivity relationships of histamine
receptors; however, relatively few bitopic ligands are yet
available for this family. As only one crystal structure is publicly
Figure 17. Histamine receptor mutation data.107,242−250,252−259,261−265 Data is shown for the consensus binding pocket defined using structure-
based generic position numbers from GPCRdb.18 Wild-type residues for the orthologues involved in mutation studies, and the mutant residue are
shown (note that only the mutations which have a data point shown in the table were actually carried out, the table is organized for comparability
among orthologues). Ligands are grouped similarly as in Figure 18. When multiple data points were available for the specific mutant−ligand
combination, the geometric mean of the fold effect values was used. See Figure 5 for color coding. Mutant numbers for each ligand and ligand
numbers for each mutant are indicated in the right side and the bottom of the heat map, respectively. The average fold effect (geometric mean) for
each mutant is also shown at the bottom of the heat map. PDF and Excel versions of the heat map are provided in the Supporting Information.
Figure 18. Histamine receptor ligands used in mutation studies.107,242−250,252−259,261−265 The cocrystallized ligand in the H1 structure is shown in
red. Chemically similar ligands to the cocrystallized ligand in the histamine receptor crystal structure are indicated with orange background, and
chemically similar ligands to any cocrystallized ligand in aminergic receptor crystal structures are indicated with a cyan background. Receptors with
available mutation data for the specific ligand are indicated along with the number of data points in parentheses. A PDF version of the figure is
provided in the Supporting Information.
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available to date for any histamine receptor, it was not possible
to analyze variation in ligand binding modes of histamine
receptors (Figures 3, 19, 20). In the amine pocket of histamine
receptors, D3×32 forms an ionic interaction with the amine
group of basic ligands, such as histamine derivatives, guanidine
or isothiourea ligands, and tricyclic amines, while residues C/
S3×36 and Y7×42 stabilize the conformation of D3×32 and
residues W6×48 and F6×51 form cation−π interaction, consistent
with mutation studies (section 7.3.1) and SAR studies,
showing the essential role of the cationic properties of the
amine group of histamine ligands. The dibenzoxepin scaffold of
the cocrystallized ligand doxepin forms hydrophobic inter-
actions with Y3×33, I3×40, W4×57, F5×47, F6×44, W6×48, Y6×51, F6×52,
and F6×55 and forms a weak H-bond interaction with T3×37 in
the major pocket between TM3−6. Mutation studies
demonstrate the important role of these hydrophobic residues
(section 7.3.2). and SAR studies demonstrate the preference of
histamine receptors for ligands with butterfly shaped double
aromatic moieties or small aromatic moieties with an optional
polar H-bond interaction functionality, mimicking the
imidazole group of the endogenous ligand. While in the H1
receptor crystal structure, N1985×461 does not form a polar
interaction with the doxepin ligand, but rather with W1584×57,
it is most probable that the analogous E5×461 in H3 and H4
interacts with the endogenous histamine and is stabilized by Y/
N4×57 from the adjacent helix. In the H2 receptor, a similar
network is possibly formed by S1504×57 and T1905×461. In all
receptors, the mutation of N/T/E5×461 underlines the
important role of this residue in recognizing histamine and
histamine analogue ligands. No structural information is as of
yet available on the interaction of minor/extracellular vestibule
residues with dualsteric histamine ligands.
7.2. Chemical Space of Histamine Receptor Ligands
in Crystal Structures and Mutation Studies. The
cocrystallized histamine receptor ligand doxepin has not
been utilized in mutation studies of histamine receptors; only
one data point for this ligand at H1 D3×32A is available.242 The
most investigated histamine ligand in mutation studies is
mepyramine (53 mutants, Figure 19). The endogenous
histamine itself has been extensively investigated (75 mutation
data points, Figure 19) at receptors H1/3/4 covering 33 different
residues in total (Figure 17), 16 of which line the binding site
in the H1R crystal structure (Figure 3). The 21 other imidazole
containing ligands cover altogether 105 (29%) of ligand
mutant combinations. Only olopatadine of the ligands
investigated in mutation studies is chemically substantially
similar to the cocrystallized doxepin, and six (10%) ligands are
pharmacophorically substantially similar to the cocrystallized
ligand (Figure 18), covering altogether 25 (7%) ligand−mu-
tant combinations. Although most compounds do not share
2D chemical or 3D shape/pharmacophore-based similarity
with the cocrystallized histamine receptor ligand, they
nevertheless represent combined ligand and receptor SAR
data sets that provide detailed information on the structural
determinants of histamine receptor binding. Terguride and
lisuride are chemically similar to cocrystallized ligands in
serotonin receptor complexes and were evaluated in mutation
studies at serotonin and dopamine receptors as well. Trans-
PAT, clozapine, and isoloxapine have also been investigated at
serotonin, muscarinic acetylcholine, and dopamine receptor
mutants, providing insights into the receptor specific
determinants of binding of these ligands by different aminergic
GPCRs.
7.3. Structural Determinants of Histamine Receptor−
Ligand Interactions. 7.3.1. Amine and Major Pocket
Mutations in Histamine Receptors. Mutation of conserved
D3×32 diminishes binding of agonists and antagonists to H1
(cetirizine, doxepin, epinastine, histamine, histaprodifen, HP-
HA, HP-HP, ketotifen, loratadine, mepyramine, methylhistap-
rodifen, olopatadine, (2S,4R)-PAT),242−246 H2 (methyltioti-
dine),247 and H4 (histamine, JNJ-7777120),
107,248 which is
consistent with the role of D1073×32 in binding the cationic
amine moiety of doxepin in the H1 crystal structure (PDB:
3RZE40). Mutation of other residues lining the amine binding
pocket, including I/L/F7×38, G/L/Q7×41, and Y/W7×42, show
receptor and ligand-dependent effects.246,249,250 The
Y4587×42A mutant decreases the affinity of the endogenous
agonist histamine, as well as the antagonists mepyramine, and
(2S,4R)-PAT but increases the affinity of the large HP-HA
agonist for H1.
246,249 Q3477×41L mutant increases the affinity
of partial agonist clobenpropit for H4.
251 The I4547×38F
mutation in H1 only affects the benzylphenoxypiperidine
antagonist compound 2 by reducing the space available for the
methyl substituent on the basic amine group. Although in the
H1 crystal structure S111
3×36 does not form a stabilizing H-
bond with D1073×32, such a feature is seen in other aminergic
Figure 19. Histamine receptor ligand binding modes and associated mutation data. (A) H1 (PDB: 3RZE
40) with docked mepyramine, a ligand
similar to cocrystallized doxepin, mutation effects mapped on structure for H1-mepyramine. (B) H1 (PDB: 3RZE) with docked histamine, mutation
effects mapped on structure for H1-histamine. (C) H4 homology model from GPCRdb with docked JNJ7777120, mutation effects mapped on
structure for H4-JNJ7777120. See Figure 5 for color coding. Mutation effects for alanine mutants were used where available.
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receptors and may be hypothesized that it plays a role also in
histamine receptor flexibility. Mutation of S1113×36 to alanine
does reduce binding of histamine and mepyramine in H1, but
mutation to polar cysteine or threonine does not have an effect
on binding of these ligands.252 However, in H4, the reverse
C983×36S mutation reduces binding of histamine and the
covalent partial agonist VUF14480, the more electron rich
cysteine being more favorable for covalent interaction with the
alkene moiety of the latter ligand.253 Mutation of the
hydrophobic residues interacting with doxepin in the H1
crystal structure generally results in decreased or abolished
ligand binding. The Y3×33A, W4×57A/F/M, F5×47A, W6×48A, and
Y6×51A mutants abolish binding of the antagonists (2S,4R)-
PAT and mepyramine to H1.
246,254 F4326×52A and F4326×52M
mutants abolish binding of seven tested ligands to H1.
245,246,254
The H1 mimicking S320
6×52F mutant reduces binding of
histamine to H4, suggesting that the polar environment is more
favorable for the small endogenous ligand to this receptor.248
F4356×55A and F6×55M mutants decrease the affinity of 4 of the
7 tested ligands, but this mutation has a smaller effect than
mutation of F4326×52.245,246,254 The mouse and rat H3
mimicking A1223×40V mutant of human H3 increases binding
of a range of ligands, identifying this residue as a determinant
of H3 species differences.
255 The polar network between
positions 4×57 and 5×461 seems to be important in all
histamine receptors, but mutation data for residue 4×57 is only
available for H1 and H4.
246,248,250,256 Mutation of W1574×57 to
the aromatic phenylalanine is detrimental to binding of
mepyramine, suggesting that the large size and/or H-bond
donor capacity of this residue are essential for ligand binding.
Mutation of N1474×57 in H4 to dog H4 (N
4×57H) and/or H3
(N4×57Y) mimicking residues reduces binding of histamine,
VUF8430, VUF5228, JNJ7777120 (Figure 19), and clozapine,
and this effect is proposed to be associated with the role of
N1474×57 in positioning E1825×461 toward the H4 ligand
binding pocket. The N1985×461A mutation in H1, T190
5×461A/
C in H2, E195
5×461A in H3, and E182
5×461A/D/Q in H4
decrease or abolish binding of most of the tested
ligands.107,242,244,245,248,250,257−259 Although mutation data is
not available in all receptors for all chemotypes, it seems that
small ligands, such as histamine and other histamine
derivatives, 2-pyridylethylamine, 2-thiazolylethylamine, guani-
dine, or isothiourea ligands are affected more by these
mutations than ligands with double aromatic scaffolds such
as histaprodifen, HP-HA, HP-HP, mepyramine, chlorphenir-
amine, cetirizine, olopatadine, and clozapine. Mutation studies
based on a guinea pig H1 homology model identified K200
5×40
as an important interaction site for the zwitterionic ligands
acrivastine, fexofenadine, and (to lesser extent) S-cetirizine.254
This H1-specific anion-binding subpocket, consisting of the
residues K17945×49, K1905×40, and H4507×34, has indeed been
confirmed by the H1 crystal structure in which this pocket is
occupied by a phosphate ion.40 L1755×40 is an important
interaction point for the chlorine substituents of indolecarbox-
Figure 20. Interaction hotspots in aminergic receptors. Median fold effects in mutation studies for each generic position aggregated for all
aminergic receptors and per subfamily mapped on example structures of the subfamilies. Color coding: cyan−white−red spectrum, where cyan,
median fold effect effect <0.3 (increased); white, median fold effect = 1 (no effect) to red, median fold effect >10 (abolished). The structures
depicted are: All, 5-HT2B in complex with ergotamine (PDB: 4IB4
31); serotonin, 5-HT2B in complex with LSD (PDB: 5TVN
61); muscarinic, M2 in
complex with QNB (PDB: 3UON101); adrenergic, β1 in complex with isoprenaline (PDB: 2Y03
157); dopamine, D2 in complex with risperidone
(PDB: 6CM437); histamine, H1 with docked (2S,4R)-PAT (PDB: 3RZE
40).
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amide and aminopyrimidines in H4 that forms a subpocket
between the extracellular region of TM5 and ECL2, which
determines subtle differences in SAR between these two ligand
classes.260 The same L1755×40 residue furthermore is an
important molecular determinant of H4 species selectivity that
explains differences in binding affinities of JNJ7777120 and
clozapine for human (L1755×40) and cynomolgus monkey
(175V5×40) H4 orthologues.
256 Stereoselective binding is
observed for R- and S-cetirizine and R- and S-chlorphenir-
amine, where both the R-enantiomers have a higher affinity for
H1R. Interestingly, the T194
5×43A mutant increases binding of
S-cetirizine but not of R-cetirizine.257,261 This stereoisomer-
specific mutational effect can be explained by docking studies
in the H1 crystal structure, which indicate that only S-cetirizine
is sterically hindered by T1945×43.11
7.3.2. Minor Pocket and Extracellular Vestibule Mutations
in Histamine Receptors. Very few mutation data points are
available for the minor pocket and extracellular vestibule in
histamine receptors. For the other aminergic receptors, more
or less indication is available for the existence of a secondary
binding pocket either in the form of a characterized allosteric
pocket (as in muscarinic acetylcholine receptors) or a transient
secondary binding pocket (as in adrenergic receptors). For
histamine receptors, however, no such information is yet
available. The phosphate pocket seen in the H1 crystal
structure is located close to the orthosteric binding pocket,
and other than zwitterionic antihistamines extending to this
pocket, only a few dualsteric antihistamines are known. The
guinea pig H1 mimicking N84
2×60S mutant of human H1 does
not affect binding of most tested ligands, except those of the
large HP-HA (and to a lesser extent HP-HP) dimer and
VUF4669 extending that far toward TM2.249 The H1
W1033×28A mutant decreases binding of histamine, mepyr-
amine, and serotonin ligands (8R)-lisuride and (8R)-terguride,
which contact the same residue in 5-HT receptors by analogy
to the known 5-HT2B-LSD crystal structure.
244 Finally, the
S15645.42A and F16945.55V mutations in the ECL2 of the
human H4 receptor significantly decrease binding of several
ligands (histamine, isoloxapine, clozapine, clobenpropit,
mepyramine, and UR-PI376); however, related residues in
the H1 receptor seem not to be available for ligand contact,
rather they probably affect the dynamics of ECL2 and
association/dissociation of ligands.256,262,263
7.4. Structure-Based Extrapolation of Histamine
Receptor Mutation Effects. Mutation data predictions
within the histamine receptor family were performed for
human data for the H1 receptor with an available crystal
structure. Results for H1 receptor: initially 160 points could be
used for mutation data extrapolation for 34 ligands at 33
mutants (14% coverage). In retrospective studies, 18% of the
points (28 data points) were retrieved, and 885 points were
predicted in prospective analysis leading to final 79% of
coverage. Accuracy of the retrospective studies was 0.66. The
heat maps referring to the original data set used for
extrapolation, and the retrospective and prospective predic-
tions are provided in the Supporting Information.
8. COMMON AND DIVERGENT DETERMINANTS OF
AMINERGIC RECEPTOR MUTATION EFFECTS
8.1. Interaction Hotspots in Aminergic Receptors.
When comparing the aggregated mutation data for each
generic position in each aminergic receptor subfamily, many
similarities but also some interesting differences may be found
(Figure 20). The characteristic D3×32 has been mutated in all
subfamilies, and its mutation is generally detrimental to ligand
binding. However, in the adrenergic receptors this mutation
results in smaller losses in ligand binding than in other
aminergic receptors (3 vs 8−15 median fold effect), possibly
because the other specific interactions with N7×38 and TM5
serines are still available. Mutation of Y7×42 in H-bond with
D3×32 also reduces binding in most cases by destabilizing the
interaction of basic amines with D3×32 (3−20 median fold
effect). The C45×50 mutation is detrimental to ligand binding in
all cases (13−22 median fold effect), but this is due to
incomplete receptor folding by the loss of the key disulphide
bridge. Residues of the hydrophobic core of the receptors at
positions 3×33, 6×48, 6×51, and 6×52 were mutated in most
subfamilies, and these mutations also abolish binding of most
ligands (6−34 median fold effect). Mutations at other
positions, however, had a larger variation in their elicited
effects. From Figure 20, it can be seen that for serotonin
receptors mutation of residues at the bottom of the binding
site were more likely to cause a large decrease in ligand
binding, while residues at the opening of the binding pocket
even increased binding (median fold effect <1 for positions
3×29, 7×35, 5×40, 45×52, and 6×58). In muscarinic
acetylcholine receptors, mutation of almost all residues
resulted in loss of effect on average, a notable exception
being the mutation of V6×55 (median fold effect 0.6), which is a
polar residue in most other aminergic receptors but a
hydrophobic one in the muscarinic acetylcholine receptors
(N6×52 one helix turn down is the characteristic polar residue in
these, which is a phenylalanine in most other receptors). In
adrenergic receptors somewhat surprisingly, the mutation of
TM5 serines considered to be important for catechol ligand
binding and receptor activation resulted in median fold effects
of 1.7−2.3, therefore it seems that the polar network of
residues in adrenergic receptors can tolerate single mutations
better than in other subfamilies. In dopamine receptors,
mutation of relatively few residues resulted in high median fold
effects. Furthermore, mutation at position 2×59 resulted in
increased effects as outlined in section 6.3, and mutations of
aromatic residues at 5×39 and 7×34 also resulted in increased
ligand binding (median fold effect 0.3−0.4). Finally, in
histamine receptors, mutation of most residues of the amine
and the major pocket resulted in abolished ligand binding
(median fold effects 3.2−20.0), but interestingly mutation of
positions 3×37 and 3×40 deep in the binding pocket resulted
in median fold effects 0.4−0.5, suggesting that ligands could be
accommodated better in a larger and deeper binding pocket.
8.2. Differential Determinants of Endogenous Ago-
nist Binding. Natural aminergic receptor agonists are
proposed to interact with polar residues at positions 5×43
and/or 5×461, as shown in the β1/2 and 5-HT1B/2B agonist
bound crystal structures and supported by mutagenesis studies.
Crystal structures and mutagenesis studies suggest that the
catechol moieties of the chemically similar agonists epinephr-
ine and dopamine adopt different binding modes in different
adrenergic and dopamine receptors. Mutation studies indicate
that both S5×43 and S5×461 play an important role in
epinephrine and norepinephrine binding to α1B, α2A, and β2,
consistent with the β2 crystal structure (PDB: 4LDO
165) in
which epinephrine forms hydrogen bonds with both S2035×43
and S2075×461. In contrast, mutagenesis studies also suggest
that the catechol moiety of dopamine interacts with S1955×43
but not with S1965×461 in D3.
233 In the other dopamine D1, D2,
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and D4 receptors, both S
5×43 and S5×461 are important for
dopamine binding, whereas mutation of S1875×43 and
S1925×461 does not affect epinephrine and norepinephrine
binding to rat α1A. This comparative analysis of receptor
mutation data indicates that there are subtle differences in the
binding modes of dopamine and epinephrine/norepinephrine
catechol between and within adrenergic and dopamine
receptor subfamilies. This observation is further supported
by the fact that the N2926×55L mutation does not affect
dopamine binding to β2, whereas the homologous H349
6×55L
mutation significantly decreases dopamine binding to D3
(Figure 16). Several residues important for 5-HT recognition
by serotonin receptors have been indicated in various docking
studies. The crystal structures of 5-HT1B and 5-HT2B have
enabled more detailed analysis of ligand−receptor interactions
within this group of receptors. Polar interactions between the
D3×32, T3×37, and Y7×42 residues have been detected, as well as
nonpolar interactions between the indole ring of 5-HT and
5×43 and 5×461 residues (serine and alanine, and glycine and
alanine for 5-HT1B and 5-HT2B, respectively).
30 These in silico
results were supported by mutation studies: D1353×32A
mutation of 5-HT2B leads to loss of the ability of 5-HT to
bind to the receptor, KD increased from 12 nM to over 10000
nM. Mutations of other residues do not lead to such significant
changes: T3×37A changed the pKi of 5-HT from 8.09 to 6.75 for
5-HT1B and from 8.41 to 6.35 for 5-HT2B. The A
5×461S
mutation changes the 5-HT affinity in different directions:
from 8.09 to 7.85 pKi modification for 5-HT1B and from 8.41
to 8.44 for 5-HT2B, whereas for Y
7×42A mutation, the pKi
change from 8.09 to 8.45 and 8.41 to 6.46 is detected for 5-
HT1B and 5-HT2B, respectively. Other residues indicated by
mutation studies as influencing 5-HT binding are 2×50, 3×36,
Figure 21. Mutation data for ligands with polypharmacological effects pooled for all tested mutants at all receptor subtypes. Data is shown for the
consensus binding pocket defined using structure-based generic position numbers from GPCRdb. Wild-type residues for the specific receptor
subtypes involved in mutation studies are indicated in the cells, and the mutant residues are shown in the header (note that only the mutations
which have a data point shown in the table were actually carried out, the table is organized for comparability among all receptor subtypes). When
multiple data points were available for the specific mutant−ligand combination, the geometric mean of the fold effect values was used. See Figure 5
for color coding.
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5×39, 5×49, 6×51, 6×52, 6×55, and 7×49. Studies of other
serotonin receptor subtypes have indicated several further
residues, mutation of which lead to significant change of 5-HT
affinity, e.g., the 6×34 position that leads to increased 5-HT
affinity after the substitution of WT residue (C3226×34K
mutation for 5-HT2A,
266 S3126×34K for 5-HT2C,
267 and
A2586×34L for 5-HT4
268): from a Ki of ∼200 nM, it fell
below 10 nM. On the other hand, both D1723×49N74 and
S2395×44A92 substitutions in rat 5-HT2A lead to much lower 5-
HT affinity in competition studies. Also, the F5×48A mutation
of 5-HT2A leads to over 10-fold lowering of 5-HT binding.
92
Deterioration of 5-HT affinity is also observed for mutants of,
e.g., D722×50 in 5-HT6,
269 T3×36,93 and N2796×55 in 5-HT4,
76
and Y3587×42 in HT2C.
95 Combined mutation and modeling
studies indicate that histamine has similar binding modes in
H1, H3, and H4 by donating a hydrogen bond to N
5×461 (in
H1)
243,245,257,258 or E5×461 (in H3, H4),
107,248,259 with its Nτ
imidazole nitrogen atom, but adopts a different binding
orientation in H2 in which N
τ and Nπ form hydrogen bonds
with D1865×43 and T1905×461, respectively.247 In H3 and H4,
the negatively charged E5×461 can furthermore form a stronger
ionic/hydrogen bond with Nτ than N1985×461 in H1, explaining
the higher affinity of histamine for H3 and H4 compared to H1.
Although there is a negatively charged aspartate at position
5×43 in H2, it has been hypothesized that an increase in
distance to the Nτ nitrogen atom might lead to the reduced
affinity for this receptor compared to the H3 and H4.
8.3. Differential Determinants of Polypharmacolog-
ical Ligand Binding.Mutation studies of ligands with various
polypharmacological profiles reveal different effects upon
particular residue mutations (Figure 21). For example, the
mutation of serine from the position 5×43 in β2 and 5-HT1A
leads to different changes in pindolol affinity (all mutations in
β2 (serine was substituted by threonine, cysteine, alanine, and
valine) result in significant deterioration of pindolol binding,
from 5- up to 68-fold186), whereas the S1995×43A substitution
in 5-HT1A leads to ∼ 2 fold68 change in the Ki of pindolol.
Another example of a similar effect is the mutation of
asparagine from position 7×38 in 5-HT1A and β2, although in
this case, it is 5-HT1A for which the effect upon mutation is
more significant: the N7×38V substitution leads to over 100-fold
change of pindolol affinity to 5-HT1A,
69 while the N3127×38Q
in β2 improves pindolol affinity (0.6 fold change) and
N3127×39T is connected with lower pindolol affinity (50-fold
change).176 Significant differences are also observed for lisuride
binding upon mutation of the 5×461 position of different
Figure 22. Distribution and fold effect of the collected mutation data points across the archetypical GPCR fold. (A) Distribution plots (frequency)
of the fold effect of the collected data points categorized into the aminergic pocket, the sodium pocket, microswitches, the G protein and arrestin
binding interface, “allosteric sites” (defined as all residue positions observed to interact with ligands in class A GPCR crystal structures outside of
the aminergic pocket), and the other remaining mutation points (“Other”). The number of residues refer to the number of unique residue positions
with available mutational data. (B) Visualization of the positions for the different mutation data points mapped onto the β2 adrenoceptor crystal
structure (PDB: 3SN6167) for each of the residues sets (except for “Other”). The spheres indicate the position of the residues and the size the
number of data points (color-coding of the spheres corresponds to the color-coding in A. A partial surface of the Gs protein is shown in pale-green,
and the agonist BI-167107 is shown in magenta sticks. For the “Other” group, only residues with a generic GPCRdb number are shown in the
residue count in A and represented in B. However, all data points (including for positions without a generic GPCRdb number) are included in the
frequency graph for “Other”.
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receptors. The S2425×461A substitution for 5-HT2A
86 and
T1965×461A for 5-HT6
87 lead to loss of high lisuride affinity (6-
and 34-fold of Ki change, respectively), whereas the A222
5×461S
mutant of 5-HT2C
86 and S1975×461A mutant of D2
230 lead to
slight improvement in lisuride binding, 0.2 and 0.7 fold change,
respectively. The D1103×32E mutation of D3 is connected with
three times lower spiperone binding,214 whereas the same
mutation in 5-HT2A does not influence spiperone affinity.
77
Different direction of changes in spiperone binding are also
observed for position 6×51 in dopamine receptors: sub-
stitution of phenylalanine into alanine for D2
244 changes the
KD of spiperone by 33 fold, whereas the F
6×51W mutation only
has a 2-fold decrease in spiperone binding affinity for D3.
Competition studies performed for 5-HT2A−WT and after
F6×51L mutation lead only to slight change in Ki values.
96
Clozapine also shows differential effects for mutation of residue
position 5×461 at 5-HT6 and D4 receptors. While the mutation
T5×461A in rat 5-HT6 results in a mild loss of affinity of
clozapine to the receptor87 (Ki increasing from 16.6 to 44.1
nM), mutation of S5×461 to alanine in the rat D4 receptor
increases the affinity of the ligand235 (Ki decreasing from 1.8 to
0.4 nM). Thus, it is seen that similar mutations can have
largely differing effects in the binding sites of different
aminergic receptors for ligands with different polypharmaco-
logical profiles. However, mutation data supporting the
understanding of differential roles of these residues is scarce,
as the sets of mutations and the sets of ligands used for
different receptors have low overlap.
8.4. Mutation Effects Outside of the Consensus
Binding Site. Of all 6692 annotated ligand−mutation pairs,
half (50.4%) cover the aminergic pocket (residue positions
defined in section 2.2). The other pairs are dispersed across the
GPCR, but several of them target functional sites such as: (i)
the coupling interface between GPCRs and G proteins and
arrestins (5.9%), with positions 12×48, 12×49, 12×51, 1×60,
2×37, 2×38, 2×39, 2×40, 2×43, 34×50, 34×51, 34×52,
34×53, 34×54, 34×55, 34×56, 34×57, 3×49, 3×50, 3×53,
3×54, 3×55, 3×56, 4×38, 4×40, 5×61, 5×64, 5×65, 5×67,
5×68, 5×69, 5×71, 5×72, 5×74, 6×23, 6×24, 6×25, 6×26,
6×28, 6×29, 6×32, 6×33, 6×36, 6×37, 6×40, 7×56, 8×47,
8×48, 8×49, 8×50, 8×51, and 8×56, (ii) the sodium pocket
(7.1%), with positions 1×50, 1×53, 2×46, 2×47, 2×49, 2×50,
3×39, 3×43, 6×44, 6×48, 7×45, 7×46, 7×49, 7×50, and 7×53,
and (iii) microswitches (13.0%), with positions 3×40, 3×46,
3×49, 3×50, 5×47, 5×50, 5×58, 6×30, 6×34, 6×37, 6×44,
6×48, 6×50, 7×43, 7×49, 7×50, and 7×53, which are all
residues involved in the (de)activation mechanism of
GPCRs270,271 (Figure 22). Mutations on these functional
sites can influence the functional state of the receptor and
thereby result in an change in ligand binding affinity. Apart
from this, 11,8% of the mutations cover ligand-binding pocket
positions outside the aminergic pocket but are observed in
ligand binding in at least one class A GPCR crystal structure
(an additional 55 generic positions). Effects on these positions
could potentially indicate inhibitors binding to allosteric sites.
However, it should be noted that some of these ligand binding
residues and the functional sites can overlap. For example,
residues interacting with the intracellular β2 adrenoceptor
inhibitor Cmpd-15 (as observed in the crystal structure
5X7D163) also overlap with the G protein and arrestin binding
interface. Overall, mutations in the aminergic binding site have
the largest effect (mean of 5.5-fold effect) on the binding
affinity of ligands (Figure 22A). However, mutations in the
sodium pocket, microswitches, and G protein and arrestin
interface can also have a pronounced effect on ligand binding
affinity. One example is the frequently mutated position 3×49
(123 data points), which is a well-known microswitch (in the
DRY-motif) and residue contact within the G protein interface.
Mutations at this position can result in a more than 100-fold
increase in affinity as seen for example for isoproterenol at the
β2 adrenoceptor. Finally, it should be noted that in the present
work, we have adopted the assumption that most of the ligands
used in mutation studies in aminergic receptors bind the
previously described consensus binding site. While this is
probably a safe assumption for basic amine containing ligands,
it is not unprecedented in the GPCR field that ligands formerly
thought to bind the orthosteric site are shown to bind distinct
allosteric sites in crystal structures. Putative muscarinic
allosteric and dualsteric ligands binding to the ECV were
indicated in section 4 and Figure 9. Similarly, the CXCR4
ligand IT1t was shown to bind only in the minor pocket/ECV.
More surprisingly, the aforementioned β2 adrenoceptor
inhibitor Cmpd-15 was shown to bind intracellularly in the
G protein-coupling interface, and also CCR2 and CCR9
chemokine receptor ligands CCR2-RA-[R] and vercirnon,
respectively, were shown to occupy an intracellular pocket.
Furthermore, in more and more GPCR structures extrahelical
membrane exposed binding sites are also revealed, such as in
FFA1, PAR2, P2Y1, C5a1, and class B receptors GCGR and
GLP-1R (see Figure 22B).10 Therefore, it cannot be ruled out
that in some cases large mutation effects outside of the amine
binding pocket indicate an alternative ligand binding mode.
However, mutation data availability is often biased by the
assumptions of functionally relevant residues of the receptors,
and such interesting mutations may not have been performed
at all.
8.5. Comparison of Mutation Effects in Binding and
Functional Assays. As pointed out earlier, only radioligand
competition, displacement, saturation, and kinetics data were
collected for the present review (data types KD and Ki). It is
generally more straightforward to associate structural mod-
ifications to ligand binding than to functional effects of the
ligands, although even the former can pose challenges as seen
in the previous section. We did not aim to evaluate mutation
effects on functional studies (such as data types IC50 and EC50)
but investigated a few references, where both binding and
functional effects were measured. Examples of mutational data
referring to functional studies were provided for representa-
tives of each receptor family. For serotonin receptors, the 5-
HT1B case was considered,
271 and the mutational effects
provided in this study were on similar level in comparison to
the affinity binding data, with the majority of data points falling
into second and third class of MUT/WT effect. A similar effect
was observed for the dopamine receptor D1.
272 The affinity
data were only slightly affected by the mutations reported in
the study (all data points were assigned to the second MUT/
WT effect class), similarly to observations from the cAMP
accumulation assay. Agonists of muscarinic acetylcholine M4
receptor were also similarly affected by mutations in terms of
ligand affinity and the functional effects examined falling into
the first and the second effect classes.120 Mutations also
similarly affected affinity and functional studies for reported
cases of adrenergic (first and second effect classes)192 and
histamine (second, third, and fourth effect classes)254
receptors. Thus, from this small comparison, it seems that
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the observed binding and functional effects are not
substantially different in aminergic GPCRs.
9. APPLICATIONS UTILIZING AMINERGIC GPCR
MUTATION DATA
Using data from mutation studies have aided various efforts to
understand GPCR structure and GPCR-ligand binding. Main
types of applications include (i) structural modeling of GPCRs
including the identification of residues crucial for proper
folding, SCAM measurements for identifying residue orienta-
tions, and combined ligand/receptor SAR studies to uncover
the structural determinants of GPCR ligand recognition, (ii)
ligand discovery and design including enhanced binding mode
prediction or virtual screening efficiency using, e.g., interaction
filters derived from mutation studies, and design of ligands
targeting specific binding pockets, displaying specific selectiv-
ity/polypharmacology profiles, or kinetics, (iii) chemical
biology applications including the design of covalent binders
to stabilize specific receptor conformations and design of
mutant receptors with altered ligand recognition profiles
(RASSLs or DREADDs). In the following, a few applications
where using mutagenesis data played a crucial role are
discussed.
9.1. Prediction of Aminergic GPCR Crystal Structures.
9.1.1. Substituted-Cysteine Accessibility to Probe the Ligand
Binding Sites of Aminergic Receptors. Before the first
experimental GPCR crystal structure was available, the
substituted-cysteine accessibility method (SCAM) was used
to map the surface of the binding site crevice, e.g., in the
dopamine D2 receptor.
273 In this method, each of the residues
in the seven TMs is mutated to cysteine, one at a time. Then,
the water accessibility of the engineered cysteines is
determined through the effects of treatment with positively
charged sulfhydryl reagents such as MTSEA. These reagents
are more reactive with the thiolate anion than with the thiol,
and only water-accessible cysteines are expected to be reactive
with the reagents. It can be inferred that a wild-type residue is
on the water-accessible surface if reaction of an MTS reagent
with the corresponding engineered cysteine irreversibly alters
radioligand binding. Furthermore, a residue can be inferred to
face the binding-site crevice if the ligand is able to retard the
reaction of the MTS reagents with the engineered cysteine.
The amino acid residues inferred to form the surface of the
binding-site crevice in the dopamine D2 receptor from SCAM
experiments were in good agreement with the highly
homologous dopamine D3 structure determined a decade
later, including residues in all TMs. Later, cysteine mutation of
the residues constituting ECL2 was also carried out, and the
reaction of five of these mutants with sulfhydryl reagents
inhibited antagonist binding and bound antagonist protected
two, I45×52C and to a lesser extent N5×36C, from reaction.274
Ligand interaction with I45×52 was also confirmed by the D3
crystal structure. Anomalous behavior of several cysteine
substitutions in TM4 of the dopamine D2 receptor (W
4×50C,
F4×54C, and L4×62C) also led to the hypothesis that TM4 forms
an interface between two D2 subunits.
275 Cross-linking at the
naturally occurring C4×59 was completely prevented by
mutating this residue to serine demonstrating that this cysteine
at the extracellular end of TM4 is part of a symmetrical
homodimer interface. The SCAM method was used to infer
binding-site crevices of mu, delta, and kappa opioid receptors
and the CB2 cannabinoid receptor as well, later confirmed by
the crystallographic structures of the opioid receptors and the
CB1 cannabinoid receptor.
276,277
9.1.2. Predicting the Crystal Structure Coordinates of
Aminergic Receptors. The strengths of using mutation study-
based constraints in modeling structural GPCR−ligand
interactions have been demonstrated in the GPCR Dock
2008,20 2010,21 and 201322 assessments to predict the crystal
structures of the A2A adenosine receptor, the CXCR4
chemokine receptor, the dopamine D3 receptor, serotonin 5-
HT1B and 5-HT2B receptors, and the class F smoothened
receptor. In the GPCR Dock 2010 challenge, at least five
groups were reported to use mutagenesis data in binding
pocket selection and deduction of key contacts for predicting
the D3-eticlopride and the CXCR4-IT1t complexes.
21 One of
the top ranking groups in the challenge25 used homology
modeling of the D3 receptor with the previously crystallized
adrenergic β2 as template. Then ss-TEA, a large-scale sequence
alignment-based method, was used to score residues according
to ligand binding probability based on the analysis of Shannon
entropies of residue positions of a multiple sequence alignment
of 7700 class A GPCR transmembrane domains.278 The most
important ligand interacting residues were predicted to be
D3×32, V3×33, S5×43, H6×55, Y7×34, and T7×38, which were
corroborated by mutation data and later confirmed by the
crystal structure.233,237 Ligand interactions were modeled using
pharmacophore searches followed by flexible receptor docking.
The structure-based pharmacophores were derived from the
important ligand binding residues identified in the previous
step using the Snooker program.279 A donor and positive
ionizable feature in the pharmacophore originated from D3×32,
an acceptor feature from T7×38, and hydrophobic features from
F6×51, F6×52, H6×55, and F7×34. The best model had TM and
ligand RMSD of 2.0 and 2.1 Å, respectively, and predicted 57%
of the correct ligand contacts. In the GPCR Dock 2013
challenge, the top ergotamine bound 5-HT1B and 5-HT2B
models that most accurately predicted the ergotamine binding
modes observed in the crystal structures were based on
experimentally supported modeling constraints,24 derived from
homologous GPCR crystal structures, mutagenesis data, and
ergotamine crystal structure information, including: (i) the
conserved salt bridge between orthosteric ligands and D3×32
observed in all aminergic GPCR crystal structures, (ii) H-bond
interactions between the indole nitrogen of ergotamine and the
side chain of S2125×43 in 5-HT1B and the backbone carbonyl of
G2215×43 in 5-HT2B based on β-adrenergic receptor mutation
studies186,280 and crystal structures,155,167 showing that S5×43 is
involved in agonist binding, and (iii) an internal hydrogen
bond observed in the crystal structure of ergotamine.
Retrospective evaluation showed that the combination of
modeling constraints resulted in 5-HT1B and 5-HT2B models
with improved ergotamine binding mode prediction and virtual
ligand screening capabilities compared to models generated
without constraints or with a single constraint. The interaction
between T3×37 and the ergotamine indole observed in 5-HT1B
and 5-HT2B crystal structures was not reflected by the limited
effect of the T3×37A mutation on ergotamine binding and was
not predicted by the models. The 5-HT1B crystal structure in
complex with chemically similar LSD, however, confirmed the
predicted interaction with S5×43, demonstrating the value of
mutation data guided GPCR modeling. Despite these
successful modeling cases, it has to be noted that the
interpretation of mutation data is not always straightforward.
As discussed in section 8.4, mutations outside of the ligand
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binding pocket may also result in high observed effects on
ligand binding or functional alteration of the receptor. Abagyan
et al. warn about the findings of the aforementioned GPCR
Dock 200820 assessment. Site directed mutagenesis suggested
at least 10 residues, in which mutations resulted in a complete
loss or significant drop in ligand affinity. However, when the
A2A receptor crystal structure became available, only four of
these residues were found to be in direct contact with the
cocrystallized antagonist.281 Carlsson et al. in their retro-
spective analysis of the GPCR Dock 201322 challenge also
write that mutation effects should be interpreted and
implemented very cautiously in model building.24 Interpreta-
tion of such data might be biased by the availability of specific
mutations, and often single mutation constraints are not
sufficient to improve predictions. Furthermore, mutation
effects may not be transferrable even to closely related
GPCRs, and changes in ligand binding for mutants should
not be considered to be sufficient evidence for a direct
interaction with a specific residue (see the analysis in section
8.4 and Figure 22). However, the present review aims to
provide comprehensive maps of residue mutations for a wide
range of ligands, which in our view can largely increase the
accuracy of ligand binding mode predictions.
9.2. Aminergic GPCR Ligand Discovery and Design.
9.2.1. Ligand Functional Effect Studies in β-Adrenergic
Receptors. Modeling studies282,283 based on the first
antagonist bound β2 adrenergic crystal structure demonstrated
that customizing the orientation of the side chains of S2035×43
and S2075×461 based on agonist vs antagonist specific receptor
mutation data185−187,280 enabled the preferential scoring of β2
adrenergic agonists over antagonists. Mutation of S5×43 affects
the affinity of both β2 adrenergic agonists adrenaline,
synephrine, phenylephrine, and antagonists isoprenaline and
derivatives, pindolol and propranolol, consistent with β-
adrenergic crystal structures (PDB: 4LDO, adrenaline;165
2Y03, isoprenaline157), in which these ligands form H-bond
interactions with S5×43. Mutation of S5×461 affects binding of
full agonists (but not of antagonists), supporting the alternative
rotameric state of this residue in the agonist bound β2
adrenergic models and later confirmed by the full agonist
bound β-adrenergic crystal structures in which the catechol or
catechol-mimicking moieties of BI-167107 (PDB: 3P0G,166
3SN6,167 4LDE165), carmoterol (PDB: 2Y02), isoproterenol
(PDB: 2Y03157), and FAUC50 (PDB: 3PDS169) containing
two (or more) H-bond donors allows for an additional H-bond
with S5×461.170 Partial agonist dobutamine (PDB: 2Y00,
2Y01157) also has two H-bond donors that can interact with
S5×43 and S5×461, but their interactions seem to be less optimal.
The use of an interaction fingerprint (IFP) scoring method
that determines ligand binding-mode similarity enabled: (i) the
prediction of binding modes of β-adrenergic ligands for which
crystal structures have not yet been solved, (ii) the selective
identification and discrimination of agonists from antagonists
in retrospective virtual screening studies, and (iii) the
prospective identification of novel β2 agonists.
170,282,284
9.2.2. Histamine Receptor Selectivity and Binding Site
Solvation. The symmetric distribution of complementary
pharmacophore features in H2, H3, and H4 binding sites (i.e.,
D3×32 in TM3 and D5×43/E5×461 in TM5) and of histamine
receptor ligands that contain two basic groups, makes binding
mode prediction challenging.107,250,260,285−288 The binding
modes of several H4 ligands, including isothioureas, indole-
carboxamides, and aminopyrimidines, in H4 have been
investigated by combining complementary in silico and in
vitro approaches.250,260 Extensive H4 SAR, mutagenesis,
docking, and MD simulation studies indicated that indole-
carboxamides and aminopyrimidines form an H-bond with
D943×32 via their piperazine amine moiety while forming H-
bond interactions with E1825×461 with their indole and
aminopyrimidine groups, respectively, and interacting with
L1755×40 with their chlorine substituent.107,260 A comparable
ligand-steered, experimentally supported protein-modeling
approach combining 3D-QSAR, MD simulations, SAR, and
mutagenesis studies indicated that clobenpropit can bind H4 in
two distinct binding modes (forming H-bonds with D943×32
and E1825×461 with their imidazole and isothiourea groups).
The addition of a cyclohexyl group to the clobenpropit
isothiourea moiety, however, allows VUF5228 to adopt only
one specific binding mode in the H4 binding pocket, in which
its imidazole interacts with D943×32 and its isothiourea group
interacts with E1825×461. Combined WaterFLAP calculations
and site-directed mutagenesis studies indicated that optimal
binding of the amine-binding region in H1 is correlated with
the presence of a trapped “unhappy” water and depends on the
character of the residue on position 7×38,251 a residue that is
highly variable in aminergic GPCRs and has been previously
related to stereoselective and subtype-selective binding. The
additional N-methyl group of the tertiary amine compound 2
shields the H-bond formed with D1073×32 from bulk water and
displaces the “unhappy” water that is trapped between
D1073×32 and I4547×38 in the secondary amine VUF14544
bound H1. The role of I454
7×38 was confirmed by the fact that
WT and I4547×38F mutant H1 had a similarly increased affinity
for compound 2 compared to VUF14544, whereas the
I4547×38T mutant does not distinguish between these two
ligands.
9.2.3. Mapping the Binding Modes of Bitopic and
Allosteric Ligands. It has been postulated that several
aminergic GPCRs possess a secondary binding pocket available
for the binding of bitopic ligands, allosteric ligands, or
transiently binding the orthosteric ligands during association
and dissociation. In the case of the muscarinic M2 receptor,
existence of this binding pocket has been proven crystallo-
graphically in the ternary complex between M2, the agonist
iperoxo, and the positive allosteric modulator LY2119620
bound between the extracellular loops as described in section
4.1 (PDB: 4MQT).34 Although mutation data for the
cocrystallized allosteric modulator is not available, the
congener LY2033298 was extensively studied in the M4
receptor.33 W4357×34 and F18645×51 were identified as crucial
residues for binding of the allosteric modulator, their mutation
to alanine completely abolishing binding. These residues form
an aromatic sandwich with the allosteric modulator in the M2
crystal structure. Molecular dynamics simulations have shown
that first-generation muscarinic allosteric modulators possess-
ing permanently charged ammonium groups also bind to this
binding pocket in the M2 receptor.
289 C7/3-phth is anchored
by two aromatic clusters, one formed by W4227×34 and
Y17745×51 and the other by Y802×60 and Y832×63. A series of
rationally designed mutations further strengthened the binding
mode hypothesis from the simulations: N4106×58Y and
N4197×31W further enhanced the cation−π interaction
strength in the first center and T4237×35E and T842×64D
formed further favorable charge−charge interactions in the
second center, thereby increasing the affinity of the allosteric
modulator. On the contrary, the N410x58K mutation in the first
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center and the Y802×60K, Y832×63K, and T4237×35K mutations
in the second center introduced unfavorable charge repulsion,
thereby decreasing the affinity of the allosteric modulator.
Similarly, in the M1 receptor, benzylquinolone carboxylic acid
(BQCA), a selective M1 positive allosteric modulator, was
shown to bind in the extracellular pocket using mutagenesis
experiments.109 From alanine scanning Y852×63 in TM2,
Y17945×51 and F182 in ECL2, and E3977×31 and W4007×34 in
TM7 were identified as residues that contribute to the BQCA
binding pocket in M1 as well as to the transmission of
cooperativity with the orthosteric agonist carbachol. Combined
SAR and mutagenesis studies also confirmed this binding
pocket for benzoquinazolinone 12, a structural analogue of
BQCA, that has a 50-fold increase in allosteric site affinity as
compared with BQCA, while retaining a similar level of
positive cooperativity with acetylcholine.52 Alanine mutations
of Y822×60, Y852×63, Y17945×51, and W7×34 largely decreased M1
binding of benzoquinazolinone 12 and/or impaired coopera-
tivity with the endogenous ligand. Conservative mutations of
the aromatic residues and SAR of the ligand suggested that the
tricyclic core of the PAM forms aromatic interactions with the
TM2 residues while the pyrazolylpyridine pendant is
sandwiched between Y45×51 and W7×34. Bitopic ligands of the
M1/2 receptors were synthesized by linking orthosteric moieties
such as atropine, scopolamine, iperoxo, and isox (an oxidized
derivative of iperoxo) with permanently charged allosteric
tetraalkyl ammonium, phthalimide and naphthalimide deriva-
tives.290,291 Furthermore, the simple ligands TBPB and 77-LH-
28-1 were also shown to act through a bitopic binding
mechanism.51 Combined mutagenesis experiments involving
residues of the orthosteric (W3×28, D3×32, Y3×33, Y6×51) and
allosteric (Y2×60, Y2×63, Y45×51, W7×34, E/T7×35) sites confirmed
that these ligands interact with both binding pockets. A large
number of bitopic ligands have been discovered for the
dopamine D2 and D3 receptors. For example, SB269652
composed of an indole-2-carboxamide moiety linked to the
dihydroisoquinoline orthosteric moiety, was demonstrated to
adopt a bitopic binding pose at one protomer of a dopamine
D2 receptor dimer.
292 Additionally, this ligand was decon-
structed to yield N-isopropyl-1H-indole-2-carboxamide, a
negative allosteric modulator of the dopamine D2 receptor.
241
Mutation of V912×60A and E952×64A were carried out, which
reduced the affinity and/or negative cooperativity of the
bitopic ligand SB269652, indicating that its indole-2-
carboxamide moiety extends into the secondary pocket
between the extracellular ends of TM2 and TM7. Furthermore,
the V912×60A mutation completely abolished the effect of the
allosteric fragment N-isopropyl-1H-indole-2-carboxamide, in-
dicating this residue as key for D2 binding. On the other hand,
the E952×64A mutation caused a 100-fold increase in its affinity
and a complete abolition of negative cooperativity with
dopamine. These results suggested that the deconstructed
fragment binds in the same region as within the parent
compound; however, the different contribution of the different
residues suggest a possibly different orientation of the
fragment. Virtual fragment screening efforts targeting the
allosteric binding site to identify bitopic/allosteric ligands of
dopamine D2/3 receptors also indicated the importance of
interactions with the extracellular ends of TM2 and TM7. In
one study, the hit fragments were linked to a nonselective
orthosteric aryl-piperazine ligand, and it was shown that
selectivity between dopamine receptor subtypes can be
modulated in the secondary pocket suggesting interactions
with the aforementioned E2×64 and Y/L1×39, S7×35, and
T7×38.293 In another study, hit fragments were shown to bind
the D3 receptor and displayed negative allosteric effects on
dopamine binding. Identified interaction motifs included polar
interactions with Y3657×34 hydroxyl and/or aromatic ring,
polar interactions with S3667×35 and E2×64 side chains, and
hydrogen bonding to the backbone amides of S1925×43,
C18145×50, and I18345×52 in the ECL2.294
9.2.4. Halogen Bonding in Serotonin Receptor Ligand
Design. Halogen atoms have been considered important for
improving ligand binding to the protein for many years,
although there are recent studies that specified their role as
formation of a specific interaction, the halogen bond.295,296 In
line with recent studies on the importance of halogen bond
formation in interaction of ligands with class A GPCRs, a series
of long-chain arylpiperazine derivatives as new ligands of D2
and 5-HT1A/5-HT7 receptors were designed and synthesized
by linking 2,3-dichlorophenylpiperazin and piperidinylsulfo-
nylquinoline moieties and identified as antagonist of the above-
mentioned receptors and for which antipsychotic and
antidepressant properties were indicated in in vivo models
(MK-801-induced hyperlocomotor activity in mice and forced
swim test (FST) in mice, respectively).297 Molecular modeling
studies supported the experimental results and indicated the
halogen interactions in the formed ligand−receptor complexes.
Introduction of a chlorine atom in the 4-position of phenyl
piperazine compounds increased affinity to D2 receptor in
comparison to unsubstituted and 4-fluoro compounds due to
postulated halogen interaction with S1935×43. Mutational data
studies also indicated significant role of this residue in ligand−
receptor affinity, with DNS, DNX, DHX, quinpirole, and
dopamine leading to 4.5-, 32.5-, 15-, 2.8-, and 177.8-fold
modification of Ki values to dopamine D2.
227 Additionally, the
shift of the chlorine atom from the 4- to the 3-position led to
improvement in affinity for 5-HT1A, 5-HT7, and D2. This effect
was justified by the stabilization of the ligand−receptor
complexes via V1905×40-mediated halogen bond in D2 and
T5×40 in 5-HT1A and 5-HT7. However, introduction of a
second chlorine atom in the 2-position of the phenylpiperazine
ring, despite formation of additional halogen bond with H6×55,
did not change affinities to the examined receptors in
comparison to the respective 3-chloro counterparts. The role
of H6×55 was also extensively examined in mutational studies
for D2 with 7-OH-DPAT and quinpirole as tested ligands, with
significant reduction of affinity upon mutation.
9.2.5. Structural Determinants of Binding Kinetics in
Aminergic Receptors. In the muscarinic M3 receptor, mutation
effects on the residence time vs the pKi of tiotropium were
strongly correlated, but mutation of some amino acids led to a
disproportionately enhanced dissociation rate.113 The most
important residues deviating from linear behavior were
N5086×52 forming concerted H-bonds with the ester and
hydroxyl groups of the ligand in the orthosteric pocket, and the
residues that form the “lid” above tiotropium, i.e., tyrosines
Y1493×33, Y5076×51, and Y5307×38. Mutation of these residues
to alanine accelerated the dissociation by up to 2 orders of
magnitude and reduced the half-life from 24.5 h to between 17
s and 8.3 min. A tiotropium analogue lacking the hydroxyl
group interacting with N6×52 was synthesized and evaluated
against wild-type and the N5086×52A mutant receptor. In the
mutant, neither tiotropium nor its analogue can interact with
N6×52 and the ratios of the Ki values and the koff values were in
the same range. In the WT receptor, there was a stronger effect
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on the koff ratios compared to the Ki ratios, thereby confirming
the important H-bond interactions. The observation of the
importance of the lid over the binding pocket on the
dissociation kinetics led to an interpretation where these
residues act as a mechanical barrier that keeps tiotropium in
the binding pocket. Furthermore, mutation of V6×55 to alanine
located in the exit channel did not reduce the affinity of
tiotropium but the half-life was reduced to less than 10 h,
indicating a further important role of this residue in controlling
the dissociation of tiotropium. The recently solved crystal
structure of the LSD-bound serotonin 5-HT2B receptor
revealed not only the unusual ligand orientation in the binding
site but also explained the unexpectedly slow on- and off-rates
at the 5-HT2B and also the 5-HT2A subtype.
61 The very slow
dissociation rate (koff = 0.022 ± 0.004 min
−1) was explained
again as the formation of a “lid” over the ligand by residues
207−214 (C45×50 to F5×36) of the ECL2 that makes it more
difficult for LSD to dissociate. In molecular dynamics
simulations the lid occasionally moved to the side allowing
LSD to start dissociation. The rationally designed L45×52A
mutant reduced the residence time of LSD from 46 to 4 min at
the 5-HT2B subtype and 221 to 50 min in the 5-HT2A subtype.
The mutated ECL2 also showed highly increased mobility in
molecular dynamics simulations. In another study, analysis of
access to the orthosteric binding sites in inactive- and active-
state β2 adrenoceptor structures provided a structural rationale
for the slowing of agonist and antagonist association.298
Intracellular binding of G protein or G protein mimicking
nanobodies stabilizes a rearrangement of the cytoplasmic end
of TM7 and ECL2 with F19345×52 and Y3087×34, moving 2−
2.5Å closer to each other to form again a lid over the
orthosteric ligand-binding site. K3057×31 also contributes to
capping the orthosteric site by trading its salt bridge with
D45×51 for an interaction with the backbone carbonyl of
F19345×52. The Y3087×34A mutant significantly diminished the
capacity of the Nb80 nanobody to slow the association of
DHAP (association half-time increased from 3.5 to 2.2 min in
the presence of Nb80) and formoterol (association half-time
increased from 2.6 to 1.3 min in the presence of Nb80).
Furthermore, the mutation also enhances the extent of
formoterol binding reflecting the capacity of the agonist
formoterol to cooperatively stabilize Nb80 binding and vice
versa. Finally, in the case of zwitterionic ligands of the
histamine H1 receptor, the effect of mutations on binding
kinetics revealed specific interactions associated with control-
ling ligand dissociation rates.261 Stereoisomers of cetirizine,
levocetirizine, and S-cetirizine are selective antagonists of the
H1 receptor with high affinity and stereoselectivity (Ki values of
6, 3, and 100 nM, respectively). The differences in affinity
come almost exclusively from the differences in the off-rate of
the enantiomers (half-life 142 min compared to 6 min). In
addition, hydroxyl or methyl ester analogues dissociate more
rapidly, with half-times of 31 and 7 min, respectively. The
importance of the carboxylic function of levocetirizine was
further supported by the results from the K1905×40A mutation.
This mutation decreased the half-life of the levocetirizine
complex to 13 min and reduced its affinity from 3 to 12 nM,
whereas the affinity and dissociation kinetics of hydroxyl and
methyl ester analogues were hardly affected. In addition to the
aminergic receptor cases described above, site-directed muta-
genesis studies have also been used to elucidate the structural
determinants of receptor−ligand binding kinetics for several
other GPCR subfamilies, including adenosine receptors
(A2A)
299 and chemokine receptors (CCR5).300
9.3. Site-Directed Mutagenesis-Enabled Chemical
Biology Studies of Aminergic GPCRs. Mutational studies
are also important for studying the mechanisms of GPCR
activation, enabling the construction of covalent ligands,
stabilizing the active conformation of the protein, and allowing
examination of its architecture in such activated states.
Weichert et al. developed a series of covalently binding agents,
derivatives of monoamine neurotransmitters noradrenaline,
dopamine, serotonin, and histamine.168 They overcome typical
problems connected with obtaining stable ligand−protein
complexes, that is, low binding affinity and rapid dissociation
rate, features characteristic for endogenous ligands. Develop-
ment of new covalent agents in the above-mentioned study
followed the disulfide-based cross-linking methodology. There-
fore, mutants of the considered proteins were constructed, e.g.,
H2×63 in the β2 adrenergic receptor was substituted by cysteine,
constructing an anchor for binding of covalent agonist
FAUC50 via disulfide bridging. On the basis of the homology
within the group of aminergic GPCRs, a general methodology
of converting endogenous neurotransmitters into disulfide-
functionalized, covalently binding molecules was developed
(examples for dopamine receptor D2, serotonin receptor 5-
HT2A, and histamine receptor H1 were presented). Analo-
gously, cysteine was introduced into position 2×63 of the
dopamine D2 receptor in replacement of leucine. The mutation
of this residue was also earlier reported, where leucine was
changed into serine.222 Saturation experiments with N-
methylspiperone revealed an almost 4-fold change of the KD
value, from 79 to 300 pM, whereas in radioligand competition
studies, the Ki of CPPMA changed from 920 to 540 nM, and
spiperone changed from 280 to 780 nM. Interestingly,
Weichert et al. observed only subtle changes of ligand binding
upon T1342×63C mutation in 5-HT2A, and only further
mutation of S1312×60 into glycine led to a covalently bound
ligand−receptor complex. In the case of histamine receptor H1,
the mutation Y872×63C led to the desired covalently bound
ligand−receptor complex. Another study reported the develop-
ment of a partial agonist of the histamine H4 receptor
(VUF14480), covalently bound to the protein, with the
identification of cysteine in position 3×36 as the residue being
an anchor point for the above-mentioned covalent bond.253
This was confirmed by mutational studies, where the C983×36S
substitution led to a decrease in pKi values of VUF14480 from
6.3 to 5.8. An adverse effect of the cysteine substitution in
3×36 position was observed for another compound examined
in this study, VUF14481, with the change in the pKi from 6.4
to 6.8. Values of pKi for the endogenous ligand, histamine,
were 8.1 and 7.2, respectively, and KD of 7 and 27 nM for wild-
type and mutant receptor, respectively. Further examination of
the structure and role of GPCRs is also possible with the
construction of so-called receptors activated solely by synthetic
ligands (RASSLs) and designer receptors exclusively activated
by designer drugs (DREADDs). Bruysters et al. exploited the
differences in binding pockets of different classes of H1
receptor agonists and identified the first Gαq/11-coupled
RASSL.252 The mutant human H1 receptor with F435
6×55A
replacement combined strongly decreased affinity (25-fold)
and potency (200-fold) for the endogenous ligand histamine
with improved affinities (up to 54-fold) and potencies (up to
2600-fold) for synthetic 2-phenylhistamine agonists. In
another study, a human muscarinic acetylcholine M3 receptor
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.8b00836
J. Med. Chem. 2019, 62, 3784−3839
3827
was constructed possessing a cyan fluorescent protein in place
of the third intracellular loop and mutations at position 3×33
(replacement of tyrosine by cysteine) and/or 5×46 (glycine
change into alanine) in the M3-RASSL.
301 Mutation of position
3×33 in M3 was also reported in the study of Tautermann et al.
(Y1493×33A).113 These changes had significant impact on the
affinity of the examined ligands (eight different compounds
were tested). For example, pKi of tiotropium changed from
10.8 to 8.6 upon mutation and that of N-methylscopolamine
from 9.8 to 7.9. The saturation studies performed on M3 and
M3-RASSL revealed 100-fold difference in [
3H]QNB affinity:
KD of 75 nM for M3 vs KD of 7.9 nM for M3-RASSL. Reduced
affinity was also observed in competition studies with atropine:
Ki of 47 nM vs Ki of 0.74 nM for M3-RASSL and M3,
respectively. Further modification of the produced constructs
by tagging at the N-terminus with an anti-VSV-G epitope and
the 20 kDa SNAP-tag sequence led to KD of 35 nM for M3 and
1.4 nM for M3-RASSL, and IC50 for atropine was 0.74 and 23
nM, respectively. However, despite the reduced affinity for
muscarinic receptor antagonists, the M3-RASSL stimulated by
clozapine N-oxide produced similar response to acetylcholine
at wild-type M3 in functional studies. The in vivo behavior of
designed muscarinic acetylcholine receptors has been recently
investigated.302
■ CONCLUDING REMARKS
Aminergic GPCRs are implicated in various diseases and
continue to be one of the most pursued drug targets.
Mutagenesis studies in the past enabled the delineation and
characterization of aminergic GPCR binding pockets and the
unraveling of crucial protein−ligand interactions for the
binding of endogenous and drug-like small molecule ligands
as well as the studying of residue substitutions affecting signal
transduction. With the elucidation of more than 50 aminergic
GPCRs to date from the five major aminergic GPCR
subfamilies (serotonin, muscarinic acetylcholine, adrenergic,
dopamine, and histamine; note that trace amine receptors have
not been investigated in mutation studies yet), this large body
of mutagenesis data can now be analyzed in the light of
experimentally determined ligand binding modes and can be
used to guide computational binding mode prediction also for
ligands that are dissimilar to the cocrystallized ones. Muta-
tional studies in the postcrystallographic era have focused on
the delineation of binding interactions of ligands with novel
chemotypes and novel binding pockets (such as allosteric
ligands) and uncovering the relationships between ligand SAR,
residue substitutions, and the way these are translated to
functional effects. Furthermore, the detailed structural under-
standing of protein−ligand interactions in aminergic GPCRs
enables the directed design of mutants for specific chemical
biology applications such as creating receptors with altered
ligand binding profiles or enabling covalent modifications.
Despite their already large contribution to understanding
GPCR structure and function, mutagenesis experiments will
continue to be indispensable for enabling crystallization of
further receptor subtypes implicated in diseases or conveying
drug side effects, studying binding pockets, and binding
interactions of novel ligand chemotypes, improving the
performance of computational methods for their prediction
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